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Breast cancer is the second most common cause of death from cancer in women, 
accounting for more than 1 million deaths globally per year. Current detection is based 
on X-ray mammographic screening, which involves the use of ionising radiation with 
potentially detrimental effects, or MRI scans, which have limited spatial resolution. The 
presence of microcalcifications in breast tissue has been associated with malignant 
disease. Unfortunately, X-ray mammography and MRI scanning techniques are not 
able to discriminate between microcalcifications from a benign lesion and those from 
a malignant lesion. 
 
The aim of this project was to use optical techniques based on vibrational 
spectroscopy, such as Fourier Transform Infrared (FTIR) absorption and Raman 
scattering, which are non-destructive, label-free and chemically specific, to investigate 
the composition of microcalcifications in breast tissue for augmented diagnostics and 
improved outcome for the patient. 
 
This work involved the characterisation of mineral standards of the type that can be 
found in the breast, in order to identify the precise composition of the 
microcalcifications. A series of calcium hydroxyapatite (Hap) compounds was used for 
calibration of the micro-FTIR and Raman spectra. The ratio of carbonate-to-phosphate 
band intensity for each individual Hap powder was determined and the data were used 
to assess the level of carbonate substitution in each breast tissue biopsy. In parallel, 
the analysis of potential precursor mineral phases (namely octacalcium phosphate and 
amorphous calcium phosphate) revealed similar features to Hap in both FTIR and 
Raman spectra, which can be translated to the biopsy samples. 
 
The accessibility to diverse panels of breast tissue sections (frozen and paraffin-
embedded) was a great opportunity to test different approaches. A deparaffinisation 
protocol was applied to a set of samples for Raman analysis and the process was 
found not to affect the microcalcification composition. The FTIR analysis of the frozen 




(1500-1400 cm-1), which normally contains a strong contribution from paraffin in 
standard histological specimens. The study of breast tissue sections showed the 
heterogeneity in composition of microcalcifications between different samples from the 
same stage of pathology in terms of protein, lipid - which is usually not observed in 
formalin-fixed paraffin-preserved (FFPE) sections - and carbonate content. 
 
The mineralisation of the MDA-MB-231 breast cell line induced by two osteogenic 
agents: inorganic phosphate (Pi) and -Glycerophosphate (G) was investigated using 
Raman micro-spectroscopy. The uptake of osteogenic agent induced a faster 
mineralisation for cells cultured with a medium supplemented in Pi (day 3) than G 
(day 11). A shift (± 3 cm-1) of the phosphate peak at 956 cm-1 in the Raman spectra 
was apparent when the culture medium was supplemented with G, indicating the 
presence of precursor phase (octacalcium phosphate) during Hap crystal formation. 
 
New IR technologies such as bright laser sources e.g. quantum cascade laser (QCL) 
open possibilities for the analysis of biological samples. They allowed us to achieve a 
better signal-to-noise ratio than Globar thermal sources used in traditional FTIR 
systems, particularly on optically dense samples such as calcifications. The ability of 
selecting specific incident wavelengths allows significant improvements in the 
acquisition time. This work illustrates for the first time the identification of 
microcalcifications using a QCL source in the long wavelength range coupled to an 
upconversion system with a silicon detector for efficient sensing. The upconverted 
images showed a good agreement with the micro-FTIR images. 
 
Vibrational spectroscopy has been shown to be a powerful tool for discrimination of 
mineral species in breast calcification. These techniques can provide complementary 
information for the pathologist to be able to classify breast pathologies - benign, ductal 
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1.1.1. Anatomy of the breast 
 
Breasts or mammary glands are part of the female reproductive system. In women, 
two mammary glands are developed during puberty with the secretion of oestrogen 
and progesterone hormones. The size varies from 30 to 1000g, depending on the 
individual’s lifestyle. In contrast, men do not have a mammary gland as developed as 
women but a rudimentary form, composed mainly of collagen and adipose tissue [1].  
From an anatomical point of view, the breast extends on the anterior chest wall and 
the pectoralis major muscle. In the horizontal axis, its projection lies from the second 
to the sixth rib. The suspensory ligaments or Cooper’s ligaments stretch over the skin 
to the pectoralis fascia providing support and mobility of the breast [1] (Figure 1.1a). 
The breast is well-vascularised by many arteries and veins, which transport oxygen 
and nutrients to the tissue. The essential blood supply of breast is the internal thoracic 
artery and its different branches [2] (Figure 1.1b). The breast is also well-drained via 
the lymphatic system formed by different lymphatic vessels and lymph nodes 
describing a circle around the nipple (Figure 1.1c). Their function, for instance, 
consists of draining tissues from dissolved substances (e.g. plasma proteins), and 
their involvement in the immune response consists of producing and maturing immune 
cells (e.g. lymphocyte and white blood cells) [3]. 
Unfortunately, if these systems (vascular and lymphatic) allow connecting mammary 
glands with the rest of the body, cancer cells could also use them to spread and 
colonise other sites (e.g. brain, lungs). 
 




Figure 1.1 Anatomy of a female breast. (a) Sagittal section. (b) Blood supply with arteries and 
veins. (c) Lymphatic system with lymph nodes. Figure adapted from [2], [4]. 
 
1.1.2. Histology and physiology of the breast 
 
As illustrated in Figure 1.1a, the breast is composed of adipose and fibrous (stroma) 
tissues surrounded by 15 to 20 lobes, corresponding to a glandular tissue. During 
lactation, the milk is drained via these lobes by lactiferous ducts through the nipple [4]. 
Each lobe is composed of 20-40 lobules. A lobule is made of around 10 to 100 acini 
that open into an intralobular terminal duct (ITD), which continues into an extralobular 
terminal duct (ETD) (Figure 1.2a and b), the lactiferous duct and the nipple. The size 
of lobules and the number of acini are different for each individual and vary according 
to the age and individual lifestyle (e.g. pregnancy, lactation) [1]. The activity and the 
growth of mammary glands depend on many hormones. For instance, oestrogen 
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stimulates the growth and multiplication of ducts, while progesterone increases the 
size of the glandular tissue (lobules and acini) [5]. As a woman gets older, her lobes 
and ducts tend to decrease and be replaced by connective and adipose tissues [2]. 
 
 
Figure 1.2 Normal breast tissue section stained with Haematoxylin and Eosin (H&E). (a) Portion 
comprising lobules composed of acini and the intralobular terminal duct (ITD) leading to the extralobular 
terminal duct (ETD). (b) Diagram of a mammary gland unit showing an acinus, the ITD and the ETD. 
(c) Illustration of an acinus (x100 magnification) with a layer of myoepithelial cells (black arrowhead). In 
the lumen, layer of epithelial cells (black arrow). Figure adapted from [1], [2], [4]. 
  
In general, two primary cell types line ducts and lobules: a basal layer of myoepithelial 
cells (stellate shape) and luminal epithelial cells, as shown in Figure 1.2c. However, 
the shape of the cells appears different depending on their location within the breast. 
For instance, the major ducts (e.g. lactiferous ducts) are lined by tall columnar cells, 
whereas the smaller terminal ducts are lined by cuboidal cells [4]. 
The childbirth produces different hormones allowing the activation of these cells. For 
example, prolactin stimulates secretion of milk proteins via the lobular epithelial cells, 
and oxytocin induces the contraction of the myoepithelial cells for the milk during 
lactation [2]. Besides, other cells are found in the breast (especially in the stroma) 
including fibroblasts, inflammatory cells, immune cells (namely macrophages) or 
microvessels, which have important functions for the breast [4]. 








In 2018, the International Agency for Research on Cancer (IARC) estimated that 
breast cancer is the fifth most common cause of death from cancer in the world with 
627,000 deaths. In women, it is the most commonly diagnosed cancer, with 2.1 million 
new cancer cases worldwide per year followed by lung cancer (Figure 1.3). Among all 
new cases of cancer diagnosed in women, 30% is for breast cancer [6]. In the UK, in 
2016, the death rate was estimated around 11,500 in women, and around 80 for men 
and the number of new cases of female breast cancer was around 54,000. Overall it 
is the second most common cause of death from cancer after lung cancer [7]. 
 
 
Figure 1.3 Ten most common causes of cancer for women associated with their number of new 
cases in 2016 [7]. 
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Survival rates tend to increase over a few decades, mainly due to changes in detection 
practice by screening population more often and earlier [6]. As illustrated in Figure 1.4, 
early diagnosis is essential for the patient to have a better response to treatment. In 
fact, the survival rate in UK is close to 100% when cancer is detected at stages I, II 
and III compared to a patient with a stage IV with only 60% survival rate [7]. 
 
 
Figure 1.4 One-year survival rate according to the breast cancer stage in women (15 to 99 years) 
in 2016 [7]. 
 
Early diagnosis is important to improve the survival rate and treatment response, and 
in this context, microcalcifications (as described below) appear to be the unique early 
marker to detect breast cancer. 
 
1.2.2. Breast cancer: Definition 
 
Due to numerous factors, changes can appear in the breast. A cell from a normal 
breast epithelium may acquire specific abilities to form a primary tumour and colonise 
other sites in the body. As shown in Figure 1.5a, over time and under control of 
different factors, cells escape from the mammary duct by Epithelial-Mesenchymal 
Transition (EMT) process; they change their phenotype from epithelial to 
mesenchymal and express different proteins to induce cell migration. In the worst-case 
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scenario, some cells can migrate from their original site and colonise other organs 
(e.g. lungs, brain …) via lymph nodes or blood vessels; these are the so-called 
metastases. In fact, during the EMT, epithelial cells must infiltrate the extracellular 
matrix (ECM) through the basal membrane in order to penetrate the blood vessel 
(intravasation). Once inside of the blood vessel, cells exit through the membrane 
(extravasation) and can interact with the microenvironment (e.g. fibroblasts …) to form 
a new tumour site [8]. 
 
 
Figure 1.5 (a) Schematic representation of cancer progression in breast tissue. (b) Different 
intermediates of ductal carcinoma. Figure adapted from [9], [10]. 
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Breast cancer is a heterogeneous disease, and its progression and outcome vary 
between individuals. This process is subject to changes in gene expression (e.g. loss 
of p53 function, overexpression of the oncogene HER2 …) [9] for modification of cell 
adhesion or cell motility or even invasion. To illustrate this heterogeneity in breast 
cancer, Figure 1.5b shows the cancer progression in mammary ducts. At the 
beginning, a normal ductal lumen contains cohesive epithelial cells (purple nucleus) 
but a group of these cells can increase their proliferation within the duct without any 
cancerous risk also called benign proliferative changes. The atypical hyperplasia, 
which is a premalignant lesion characterised by an abnormal proliferation of cells in 
healthy breast parenchyma, could lead to a ductal carcinoma in situ (DCIS) and 
eventually an invasive carcinoma. The risk of developing an invasive ductal cancer 
(IDC) increases for each stage of the disease, but for the pathologist, it is still 
challenging to discriminate which case will evolve into a malignant lesion [9]. 
 
1.2.3. Histological and molecular classification 
 
In order to standardise the disease, to help clinicians and histopathologists but also to 
improve diagnosis and treatment, different classifications have been introduced. The 
morphological and histological appearance of breast tumours can be associated with 
the degree of malignancy of the lesions. Classifications can also be based on the 
molecular marker expression of tumour and the metastatic process.  
 




Figure 1.6 Classification of breast cancer subtypes. (H&E staining) A: Comedo, B: Cribiform, C: 
Solid, D: Micropapillary and E: Papillary. Figure adapted from [11]–[13]. 
 
As shown in Figure 1.6, breast cancer is divided into two main groups: carcinoma in 
situ and invasive carcinoma. 
Firstly, carcinoma in situ is separated into two types according to the original site of 
the primary tumour. When the tumour takes place in ducts, it is called ductal carcinoma 
in situ (DCIS), whilst when it originates in the lobules, it is called lobular carcinoma in 
situ (LCIS) [11]. DCIS is the most common carcinoma in the breast with around 80-
90% of all in situ carcinomas [12]. The DCIS group is more heterogeneous than LCIS 
with six subtypes based on histopathology characteristics: Comedo, Cribiform, 
Micropapillary, Papillary and Solid types [11]. 
 
Secondly, the invasive carcinoma group is also classified in six subtypes: tubular, 
ductal or lobular, invasive lobular, IDC (which is involved in 70-80% [12] of all invasive 
lesions), mucinous and medullary [11]. 
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Elston and Ellis have also subclassified DCIS, LCIS and all invasive tumours in three 
grades [14]. A score reflects the differentiation and proliferation of tumour cells [12]: 
- Grade 1: well-differentiated. Tumour cells appear normal and are not overgrowing. 
- Grade 2: moderately differentiated. Cells appear slightly different than normal. 
- Grade 3: poorly differentiated. Cells appear abnormal and tend to grow and spread 
more aggressively. 
 
Clinicians can also stage breast cancer and guide the surgery using the Tumour Node 
Metastasis (TNM) staging system. This system, which is the “gold standard”, has been 
developed by the American Joint Committee on Cancer (AJCC) to standardise 
diagnostics, estimate prognosis and select an appropriate treatment for each 
individual. Three parameters are taken into account in this system: the size of the 
primary tumour (T), the involvement of the lymph node (N) and the spreading of 
cancer. (M) describes the presence of distant metastases, which colonise other 
organs. More details of this classification are presented in Table 1.1. 
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Table 1.1 TNM staging system adapted from [15]. 
 
(T) Primary tumour 
Tx- Primary tumour cannot be assessed 
T0- No evidence of primary tumour 
Tis- Carcinoma in situ (DCIS, LCIS, Paget’s disease) 
T1- Tumour ≤ 2 cm 
T1mic- Microinvasion ≤ 0.1 cm 
T1a- Tumour 0.1-0.5 cm 
T1b- Tumour 0.5-1 cm 
T1c- Tumour 1-2 cm 
T2- Tumour 2-5 cm 
T3- Tumour > 5 cm 
T4- Tumour of any size with direct extension to chest wall or skin 
T4a- Extension to chest wall 
T4b- Oedema or ulceration of the skin or satellite skin nodules 
T4c- Extension to the chest wall and the skin 
T4d- Inflammatory carcinoma 
(N) Regional lymph Node 
Nx- Regional lymph nodes cannot be assessed 
N0- No regional lymph node metastasis 
N1- Metastasis in axillary lymph nodes mobile 
N2a- Metastasis in axillary lymph nodes fixed 
N2b- Metastasis in internal mammary node but not in axillary lymph node 
N3a- Metastasis in infraclavicular lymph node and axillary lymph node 
N3b- Metastasis in internal mammary lymph node and axillary lymph node 
N3c- Metastasis in supraclavicular lymph node 
(M) Metastasis 
Mx- Distant metastasis cannot be assessed 
M0- No distant metastasis 
M1- Distant metastasis 
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1.2.4. Biomarkers of breast tumour 
 
All these classifications are not enough to have an adequate and successful treatment 
for each patient. The search for predictive biomarkers associated with breast cancer 
and expressed by tumour cells are necessary [9]. Amongst these biomarkers, the well-
known and well-established are: oestrogen receptor (ER), progesterone receptor (PR) 
and Human Epidermal Growth Factor Receptor 2 (HER2) [11]. For instance, ER, which 
is the most important predictive marker in breast cancer [16], [17], is overexpressed 
(ER+) by luminal epithelial cells in over 70% of DCIS cases [9]. In fact, its expression 
determines the patient response to hormone therapy. In the case of PR, its expression 
is often associated with ER expression [18]. Less than 1% of all cancers is ER-/PR+ 
[17]. HER2 is a proto-oncogene enabling cell growth and proliferation and 
overexpressed (HER2+) by epithelial cells in 50% of DCIS lesions [9]. Slamon et al. 
suggested that the HER2 subtype is related to a poor prognosis for the patient [17], 
[19]. 
According to the expression of these biomarkers, breast cancer is divided in molecular 
subtypes. The predictive markers are evaluated by immunohistochemistry. Table 1.2 
summarises the breast cancer molecular subtypes according to their 
immunohistochemistry status (IHC), the expression of their genes of proliferation (i.e. 
Ki67), histologic grade and prognostic. Six molecular subtypes were identified: luminal 
subtypes A and B, normal breast-like, HER2 enriched, basal-like and claudin-low [11], 
[18], [20], [21]. 
 
Table 1.2 Classification of molecular subtypes of breast cancer. IHC: Immunochemistry status. 
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The clinical tests of these biomarkers are important to evaluate the treatment and the 
outcome of the patient. For instance, the luminal subtype A and B of breast cancer 
have different outcomes. In fact, patients with luminal A subtype of breast cancer have 
a good prognosis while luminal subtype B is more aggressive, with a higher expression 
of gene proliferation [20]. The normal breast-like subtypes are not well characterised 
and represent 5 to 10% of all breast carcinomas [20]. The tumours with HER2 enriched 
subtype have a high proliferation level with a high histological grade [20]. In the case 
of a basal-like subtype (triple-negative), the prognostic is poor [11]. In this case, 
hormone therapy appears useless and requires surgery or chemotherapy. The 
claudin-low subtypes are identified by a low expression of genes responsible for tight 
junctions, the cohesion between cells. These tumours express genes involved in the 
EMT [20]. The tumours presenting this subtype have a high histologic grade and poor 
prognosis.  
The heterogeneity of breast tumours tends to challenge the treatment. These 
biomarkers are considered as a reference and need to be identified to improve the 
patient outcome. 
 
1.3. Risk factors 
 
In 2012, it was estimated that around 10-12% of women worldwide would have breast 
cancer during their life. Many studies highlight the fact that the risk for developing 
breast cancer increases with genetic, lifestyle and hormonal factors. 
 
1.3.1. Genetic factors 
 
Family history is significant for breast screening. In fact, in those cases where there is 
a high-risk potential, a screening mammography every year is recommended. It has 
been estimated that family history is responsible for 27% of all breast cancer cases 
[22]. In 1866, Broca highlighted a correlation between breast cancer and inheritance 
[23]. 
Numerous genes are responsible for the development of breast cancer and they are 
classified in different categories according to their involvement in breast cancer. The 
most known genes are BRCA 1 and BRCA 2 (Breast Cancer 1 and 2) and are the 
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high-risk breast cancer susceptibility genes [23]. They are involved in 3-6% of all 
breast cancers [22]. These genes are considered as the “caretaker” of DNA because 
of their involvement in its repair process. A mutation in these genes could lead to 
cancer [23]. 
It has also been demonstrated that a combination of high breast tissue density 
observed by mammography with a nulliparity, increases by seven fold the risk to 
develop breast cancer [22]. These cases are considered as having a high-risk potential 
and need to be considered for breast screening. The breast density is classified 
according to the American College of Radiology Breast imaging reporting and data 
system (ACR BI-RADS) classification (Figure 1.7). 
 
 
Figure 1.7 Mammograms showing different breast densities classified according to the American 
College of Radiology (ACR). (a) ACR 1: fatty tissue, (b) ACR 2: fibroglandular tissue, (c) ACR 3: 
heterogeneously dense and (d) ACR 4: extremely dense, [24]. 
 
Surprisingly, height could also be a factor for developing breast cancer. In fact, tall 
women (1.70 m) have a higher potential to develop cancer than smaller women (1.55 
m) [22]. 
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1.3.2. Lifestyle risk factors 
 
Numerous factors could induce breast cancer. Among these factors, alcohol, smoking, 
obesity and fat diet. Physical activity can reduce the risk of breast cancer by 20% [23]. 
Furthermore, pregnancy after 35 years old increases the risk, whilst pregnancy before 
29 years old decreases the risk [22]. Radiation exposure or pollution have been 
demonstrated to increase the risk of breast cancer in women [23]. 
 
1.3.3. Hormonal factors 
 
Endogenous hormones (menstrual cycle) and exogenous hormones (Hormonal 
Replacement Therapy (HRT) and contraceptive pills), and in particular the oestrogens, 
play a role in breast cancer. A long exposure to this hormone has been identified to 
be a risk factor. In fact, the oestrogen receptors related to the hormonal activity are 





Microcalcifications consist of abnormal calcium deposits in the mammary gland and 
were described for the first time in 1951 by R. Leborgne. They are, at some point, a 
risk factor to develop a breast cancer. Microcalcifications have a small size (< 0.5 mm 
in diameter) and are evidenced in mammographic screening as tiny and clustered 
inclusions. When a breast tumour is not palpable, search for microcalcifications could 
be a predictive marker for breast cancer. In fact, it has been demonstrated that 
microcalcifications are correlated with breast cancer [25]. Tabar et al. have shown over 
20 years, that a regular invitation for screening reduces by 30% the breast cancer 
mortality. A comparison has been made between a group of populations without 
invitation for screening and a group with a regular follow-up. The results demonstrated 
that mammography is a tool for an early detection of tumours based on 
microcalcification features and also by discriminating high risk tumours (small or non-
palpable). This improves chances for survival and the ability to discriminate cancer 
with poor or good prognostic [26], [27]. 





Microcalcifications are considered as the unique early marker of breast cancer [28]. 
Many studies suggest that there is a correlation between the appearance of 
microcalcifications and lesion malignancy. 
 
1.4.1.1. Le Gal’s classification 
 
Le Gal’s classification was introduced in 1984 and aims to distinguish 
microcalcifications based on their morphological appearance by associating a 
predictive value of malignancy [29]. In this classification, microcalcifications are 
grouped in five categories, as illustrated in Figure 1.8. For instance, ring shaped 
microcalcifications are involved in 100% of benign lesions whilst vermicular 
microcalcifications are observed in 100% of malignant lesions [25]. 
 
 
Figure 1.8 Le Gal’s classification of microcalcifications based on their mammographic appearance 
and related percentage of correlation with malignant lesions in breast cancer. 
 
Le Gal’s classification is easy to use for classifying microcalcifications; however, it 
does not consider the spatial distribution of microcalcifications in a mass or even their 
margins. In this context, another classification is needed to include these parameters. 
 
1.4.1.2. BI-RADS classification 
 
The American College of Radiology (ACR) Breast and Imaging Reporting and Data 
System (BI-RADS) has been introduced in 1993. The purpose of this report was to 
standardise the results from mammographic images, within the radiologist community. 
A description and classification, in specific terms, of the breast lesions and 
microcalcifications associated with a predictive value of malignancy help clinicians to 
Chapter 1 : Introduction 
16 
 
establish an adapted treatment for the patient. In this classification, microcalcifications 
are defined by their morphology, size and distribution within the mammary gland. 
The morphology of microcalcifications is classified into two main categories [24], [30], 
[31]: 
1. Typically benign 
The calcifications are grouped into nine categories, and few examples are illustrated 
in Figure 1.9: 
- Skin or dermal: Lucent centre and usually localised near or within the skin (from the 
sebaceous gland). 
- Vascular: Tubular structure and a railroad form. They are associated with blood 
vessels. 
- Coarse or “popcorn-like”: Large size (< 2-3 mm diameter) and usually associated 
with fibroadenomas. 
- Large rod-like: calcium deposit into a dilated duct leading to the nipple. The size is 
usually more than 1 mm. 
- Round: Spherical shape with different sizes. When they are smaller than 0.5 mm, 
they are called “punctate” or “pulverulent”. 
- Rim (“lucent-centred” and “eggshell” calcifications): Deposit of calcium at the surface 
of a sphere. The eggshell shape has less than 1 mm size, whereas lucent-centered 
calcifications have a size comprised between 1 mm and more than 1 cm. 
- Suture: calcium deposit on suture material. 
- Dystrophic: Associated with a prior trauma surgery or radiation; this type represents 
most of the cases in breast pathology. They are larger than 1 mm. 
- Milk of calcium: Sedimented calcifications in cysts. They have different appearance 
such as linear, curved or “tea-cup” shape. 
 




Figure 1.9 Different type of typically benign calcifications based on the BI-RADS classification 
using mammographic images. (Aa) Vascular, (Ab) coarse or popcorn-like, (Ac) large rod-like and (Ad) 
round calcifications. Rim type is represented by (Ae) “eggshell”, (Af) lucent-centred. Finally, (Ag) suture 
and (Ah) milk of calcium calcifications, [24]. 
 
2. Suspicious morphology 
In this group, the calcifications have a low or high risk of malignancy [30], and they are 
illustrated in Figure 1.10: 
- Coarse heterogeneous: Irregular and usually between 0.5-1 mm in size (13% risk of 
malignancy). 
- Amorphous: They do not have any specific form, usually tiny and hazy. There is 27% 
risk of malignancy. 
- Fine pleomorphic: Irregular shape and smaller than 0.5 mm. There is 78% risk of 
malignancy. 
- Fine linear or fine linear branching (casting type calcification): Smaller than 0.5 mm, 
they can be linear, curved or branched. They represent 78% risk of malignancy and 
are usually associated with a very poor prognosis for the patient [32]. 
 




Figure 1.10 Mammographic images of calcifications with suspicious morphology based on the BI-
RADS classification. (a) Coarse heterogeneous, (b) amorphous, (c) fine pleomorphic and (d) fine linear 
or fine linear branching calcifications, [30]. 
 
According to the BI-RADS classification for mammography reports, the radiologist 
classifies calcifications based on their spatial distribution. They are divided into five 
groups [33] and illustrated in Figure 1.11: 
- Diffuse: Calcifications are randomly distributed in the breast. 
- Regional: Calcifications are localised in a larger area of the breast (larger than 2 cm). 
- Linear: Calcifications present a linear arrangement. The calcium deposit was mainly 
in a duct. 
- Segmental: The calcium deposit is localised in ducts and branching. 
- Grouped: Several calcifications (usually five) are grouped in a small area of the breast 
(1 cm) or a larger number clustered in 2 cm of breast tissue. 




Figure 1.11 Classification of calcifications based on their spatial distribution according to the BI-
RADS classification. (A) Diffuse, (B) regional, (C) linear, (C) segmental and (D, E) grouped. Figure 
adapted from [24], [33]. 
 
All these calcification features enable to improve the clinical outcome of the patient 
when they are detectable by mammography. Based on the morphology and the spatial 
distribution of calcifications, radiologists are able to manage mammography reports 
into five mammographic grades (normal, benign, probably benign, suspicious of 
malignancy and highly suspicious) [34] summarised in Table 1.3. 
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Table 1.3 BI-RADS categories for mammography reports. Categories based on the calcification 
appearance and their distribution in the breast tissue. Adapted from [24], [34]. 
 
For instance, in diffuse distribution, an amorphous calcification is always benign. 
Conversely, a linear or segmental distribution (a calcium deposit is localised in ducts 
and branching) could be indicative of a high risk of malignancy. However, it depends 
on the morphology of the calcifications: a vascular shape in a linear distribution is 
benign, and it is the same case for a regional distribution [33]. 
These features show the complexity of mammogram interpretation to predict the 
malignancy of breast lesions. Further complementary analysis such as a biopsy is 
often required to establish a diagnosis. 
 
1.4.2. Composition of microcalcifications 
 
In 1984, Frappart et al. demonstrated the existence of two types of microcalcifications 
by X-ray diffraction according to their chemical composition. Type I microcalcifications 
are composed of calcium oxalate dihydrate (COD), whilst type II microcalcifications 
are mainly composed of hydroxyapatite (Hap) [35]. 
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1.4.2.1. Calcium oxalate dihydrate (COD) 
 
The COD crystal (so-called “weddelite”) is amber, crystalline and bi-refringent. The 
formula is CaC2O42H2O. They are observed in benign breast lesions [35]. It has been 
mentioned that calcifications with a “milk of calcium” morphology are small particles of 
COD [33]. 
 
Figure 1.12 Example of type I microcalcification from a sclerocystic mastopathy observed by 
scanning electron microscopy, x980 magnification. Image from [35]. 
 
Figure 1.12 shows a well-defined crystal with homogeneous surface and a typical 
pyramidal shape.  
 
1.4.2.2. Calcium Hydroxyapatite (Hap) 
 
The Hap crystal is white, opaque and non-refringent under polarised light. The formula 
is Ca10(PO4)6(OH)2 [35]. 
 
 
Figure 1.13 Example of type II microcalcification from an infiltrating adenocarcinoma of the breast 
observed by scanning electron microscopy, x1800 magnification. Image from [35]. 
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Figure 1.13 illustrates a microcalcification with an irregular surface, with oolites (egg 
stones) composed of Hap without any crystallinity. 
Frappart et al. also demonstrated that type II microcalcifications are associated with 
benign and malignant lesions. They appear to be smaller in the case of suspicious 
lesions and larger with a specific appearance in benign lesions [33]. 
 
Hap crystal is the main compound found in bone and teeth. The study of biological 
tissues containing Hap suggests that Hap crystals are not found in their pure form, but 
are mainly carbonated Hap (cHap). Two carbonate ion subtitutions are found in the 
crystal. When OH- ion is replaced with CO32- ion, we talk about type A substitution, 
and when PO43- ion is repaced with CO32- ion, we talk about type B substitution [36]. 
Sometimes, type L (labile) substitution can be found when the CO32- ion is at the 
surface of the hydration layer of Hap [37]. Different levels of substitution are found in 
the body: 5.6 wt% of CO32- ion substituted in bone, 4.6 wt% of CO32- ion in dentine and 
3.2 wt% of CO32- ion in enamel [38]. The formulae of Hap containing different 
substitutions are: 
- Type A: Ca10(PO4)6(OH)2-2y(CO3)y 
- Type B: Ca10(PO4)6-x(OH)x(CO3)2-x 
 




Figure 1.14 Schematic diagram illustrating type A and type B CO32- substitutions in Hap crystal. 
Image from [39].  
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However, other elements can be incorporated in the carbonated apatites directly in the 
crystal lattice or just absorbed at the surface of the crystal, including F-, Cl-, SiO44-, 
CO32-, Na+, Mg2+, K+, Sr2+, Zn2+, Ba2+ and Al3+ [40]. These substitutions are possible 
due to a rich environment in various ions. In fact, it has been demonstrated that breast 
tumours are rich in magnesium, potassium, zinc etc. and could potentially interact with 
the Hap crystal [40], [41]. Anionic substitutions can replace PO43- or OH- ions, whereas 
cationic substitutions replace only Ca2+ ion. The incorporation of these elements in the 
Hap lattice affects crystal structure but also crystallinity and solubility, inducing 
changes in the surrounding environment [40]. 
 
1.4.3. Formation of microcalcifications 
 
The mechanisms involved in microcalcification formation and the relationship between 
their occurrence and cancer progression are still poorly understood [25]. This section 
is an overview of different models of microcalcification formation found in the literature, 
even though the different mechanisms have not been fully clarified yet. 
 
 
Figure 1.15 Different mechanisms of microcalcification formation in breast cancer cells. MV: matrix 
vesicle, ECM: extracellular matrix, Pi: inorganic phosphate. 
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1.4.3.1. Matrix vesicles (MVs) 
 
MVs are generally found in cells and they are able to induce mineralisation in a 
physiological process, e.g. osteoblasts and chondrocytes, but it has not been excluded 
that they could also be involved in a pathological process. Their size varies between 
20 and 200 nm in diameter [25]. As illustrated in Figure 1.15, MVs are the result of the 
invagination of the cell membrane at specific sites. They contain at their surface 
different channels (specific to calcium or phosphate ions) that facilitate Hap crystal 
formation, but the exact composition of these crystals is unknown. Finally, once the 
first Hap crystals are produced, they are released through endocytosis into the ECM 
followed by maturation. 
 
1.4.3.2. Role of Bone Morphogenetic Proteins (BMPs) 
 
Breast cancer cells must acquire osteoblastic characteristics to induce the 
mineralisation process (Figure 1.16). Some breast epithelial cells undergo the EMT 
and acquire a mesenchymal phenotype. Following these changes, and under the 
overexpression of the bone morphogenetic protein 2 (BMP-2), which is an osteogenic 
inducer, the mesenchymal cells appear to change their phenotype into osteoblast-like 
and are able to secrete Hap crystal [25], [42]. 
 
 
Figure 1.16 Simplified model of breast epithelial cells that acquire osteoblast characteristics via 
EMT, followed by expression of bone morphogenetic protein 2 (BMP-2) and then secretion of Hap 
crystal from the invasive/infiltrating front of a breast tumour. EMT: Epithelial mesenchymal transition. 
Adapted from [25], [42]. 
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Although there are many osteoblastic matrix proteins, e.g. osteocalcin and 
osteopontin, that are capable to induce mineralisation, BMP-2 seems to play an 
important role in breast microcalcification regulation [25]. For example, BMP-2 
expression increases calcium channel expression at the surface of breast cancer cells, 
which increase Ca2+ ions content into the MVs. 
 
1.4.3.3. Apoptotic bodies 
 
They come from programmed cell death (necrotic areas) and promote 
microcalcification formation by accumulating calcium and phosphate ions at their 
surface. Their role in the mineralisation has not been investigated [28]. 
 
1.4.3.4. Intracellular mineralisation 
 
As illustrated in Figure 1.15, it has been demonstrated that calcium and phosphate 
ions can precipitate into the cytoplasm of osteoblast-like cells and, after release in the 
ECM, the maturation process takes place. 
The MVs and the intracellular mechanisms tend to confirm that microcalcification 
formation is a secretory process rather than mineralisation from necrotic areas [28], 
[43] but it is subject to controversy in the literature and is still not clear. 
 
To summarise the mineralisation process, three pathways of pathological 
mineralisation are considered [43] (Figure 1.17): 
- Unregulated: including the formation of apoptotic bodies and formation of 
microcalcifications in a necrotic area. 
- Regulated: breast cancer cells undergo the EMT and change their phenotype to 
become osteoblast-like cells (involving BMPs expression and MVs). 
- Dysregulated: imbalance between inducers (e.g. BMPs) and inhibitors (e.g. 
osteopontin). 
 




Figure 1.17 Scheme of the three different pathways of pathological mineralisation: unregulated, 
regulated and dysregulated. 
 
1.4.4. Models of in vitro mammary cell mineralisation 
 
To improve the understanding of the pathological process, Morgan et al. developed 
an in vitro model of mineralisation based on the secretory theory (Figure 1.18) [28]. To 
produce Hap crystals, cells need a source of inorganic phosphate (Pi). In this model, 
they added in the culture medium β-glycerophosphate (βG), which is an osteogenic 
agent, commonly used in literature. It has been demonstrated that the enzyme ALP 
(alkaline phosphatase) present at the surface of mammary cells can hydrolyse βG to 
Pi and glycerol. The Pi produced is then absorbed by cells via Na-Pi co-transporters. 
Once inside the cell, Pi can precipitate with calcium to produce the first Hap crystals. 
The primary crystals are then released in the ECM by different mechanisms, as 
discussed above. To regulate this process, osteopontin (OPN) can be produced to 
inhibit Hap growth as well as inorganic pyrophosphate (PPi). In pathological 
conditions, both can be inhibited by ALP to regulate the crystal growth and enhance 
cell malignancy. This model is based on a secretory process of pathological 
mineralisation. 
 




Figure 1.18 Model of in vitro mammary cell mineralisation. βG: β-glycerophosphate, G: glycerol, Pi: 
inorganic phosphate, PPi: inorganic pyrophosphate, Ca: calcium, ALP: alkaline phosphatase, Na: 
sodium, HA: hydroxyapatite and OPN: osteopontin, [28]. 
 
Vidavsky et al. suggested that this model constrains mineralisation to upregulate ALP 
expression. They developed an alternative model of mineralisation based on 3D 
culture, which they consider more appropriate than 2D culture. Their model is based 
on the development of microcalcifications in necrotic areas. They formed different 
spheroids with a necrotic core and could simulate benign, DCIS and invasive lesions. 
 
 
Figure 1.19 Model of 3D in vitro mammary cell mineralisation. OPN: osteopontin and ALP: alkaline 
phosphatase, [43]. 
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In this model (Figure 1.19), MCF-10a cells (normal breast epithelial cells) are 
considered as a benign lesion. Before the experiments, they modified genetically the 
MCF-10a cells to have MCF10DCIS and MCF10CA1a cell lines. At the end, they 
obtained three different cell lines, which simulate the different stages of cancer: 
benign, in situ and invasive breast cancer. Then, they started to grow the cells in a 
culture medium supplemented in magnesium, calcium and phosphate at physiological 
concentrations to induce the microcalcification formation. By avoiding the use of 
osteogenic agents (e.g. βG), they recreated physiological conditions to induce 
microcalcifications which is maybe not the case by using osteogenic cocktails. 
However, the formation of microcalcifications in vivo or how they interfere during 
cancer progression is still unknown. 
 
1.4.5. Relationship between microcalcification and breast cancer 
 
As discussed above, the shape and the composition of microcalcifications are 
associated with the pathology outcome. In this context, it is interesting to find the 
relationship between microcalcifications and the occurrence of breast cancer. For 
instance, Morgan et al. have demonstrated that Hap crystal could induce matrix 
metalloproteinases (MMPs) expression in MCF-7 and Hs578T cell lines (two malignant 
breast cancer cell lines). MMPs are involved in the degradation of ECM components 
and promote invasion of breast cancer cells [44], [45]. In addition, the same team found 
that Hap crystals are involved in cell proliferation by enhancing mitogenesis in normal 
and malignant breast cancer cell lines [45]. Finally, it has also been demonstrated that 
Hap crystals induce an inflammatory process and upregulate different factors to 
enhance breast tumour development [45]. 
 
1.4.6. Involvement of microcalcifications in other diseases 
 
The pathological mineralisation occurs in different locations of the body such as 
vasculature, lung, prostate, kidney or brain. Investigation of other forms of calcification 
is useful to understand the phenomenon that occurs in breast cancer. Scimeca et al. 
demonstrated that calcifications involved in prostate cancer are produced via cells 
acquiring osteoblast phenotype through the EMT [42]. However, in this pathology, 
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calcifications are often associated with benign lesions and rarely with malignant 
lesions [46]. In lung calcifications, the shape is important to determine the degree of 
pathology. A benign pulmonary nodule generally presents calcifications with a dense 
core, or they are laminated or diffuse, whilst malignant lesions contain punctate or 
eccentric calcifications [47]. The mineral composition varies in kidney calcifications. 
Monk et al. have suggested that the composition changes based on geographical 
distribution. In Europe 75% of calcifications are made of uric acid, while in the US they 
are made of calcium oxalate or calcium phosphate; in the UK struvite stones 
(magnesium ammonium phosphate) are more important [48]. These examples show 
that the occurrence of calcifications is complex, and the maturation of calcifications is 
not a linear process and not well-known. 
In the meantime, regarding this lack of knowledge, a screening of the population is the 
best option to identify and rapidly treat those individuals affected by breast cancer. 
 
1.5. Screening, diagnostics and prevention 
 
In England, all women aged 50 up to 71 years old receive a letter for a routine 
screening every three years. The cost for routine screening is around £169 million per 
year but mammography is a powerful tool for detecting breast cancer. According to 
the report from the National Health Service (NHS) in England, in 2017-18, 2.5 million 
women were invited, around 1.8 million attended their appointment for mammography, 
and 18000 cancer cases were detected (14000 of those cancers were invasive) [49]. 
 
1.5.1. Clinical exam 
 
The first step towards detection of breast cancer is any change in breast appearance 
or the presence of a fluid discharge as illustrated in Figure 1.20. If that is noticed, an 
appointment with a doctor could be necessary, and the GP can recommend further 
investigations, e.g. breast palpation and/or screening mammography. 
 








Mammography is a medical imaging test that uses low-dose X-rays to visualise breast 
tissue (Figure 1.21). As illustrated in Figure 1.21, a mammogram presents fat tissue 
in a very dark colour, water in dark, connective tissue is lighter, and calcium is white. 
A good quality mammogram is generally obtained with a strong compression of the 
breast. The compression helps to immobilise the breast, decrease the thickness and 
have a tissue imaged with high contrast [27]. Low energy X-rays are used to provide 
a contrast in soft tissues, but limited penetration can impact on the quality of the 
images when measuring thick or dense breasts. 
 
 




Figure 1.21 A typical screening mammography. (a) Mammography in mediolateral oblique position 
and (b) related mammogram. (c) Mammography in craniocaudal position and (d) related mammogram, 
[27]. 
Mammography assists the early detection and diagnosis of breast cancer because it 
can screen non-palpable breast lesions by detecting microcalcifications. However, it 
is impossible by mammography to distinguish type I or II microcalcifications or 
discriminate between benign and malignant lesions. Therefore, if an area appears 
suspicious in mammography, further investigation such as a biopsy is necessary. 
Breast cancer cannot be accurately diagnosed without a biopsy that can help the 




If a suspicious area is found during routine screening, a protocol has been established 
to manage patients and their outcome, as shown in Figure 1.22. 




Figure 1.22 Protocol of assessment following the evidence of abnormalities (microcalcifications) 
during routine screening. VACB: vacuum-assisted core biopsy, [51]. 
 
According to the NHS Breast screening programme, if a microcalcification is detected 
during routine screening, a new mammography is performed (unless the abnormality 
is easily identifiable). If the lesion is benign, the patient will be recalled for routine 
screening every three years. If not, a clinical examination and ultrasound analysis are 
performed. During this analysis, a marker clip is inserted in the lesion area to guide 
the needle biopsy procedure. 
Once the biopsy procedure has been performed, an H&E staining, which is the “gold 
standard” for histological diagnosis, is realised on samples to help the pathologist to 
discriminate between different tissue structures. Biopsies are then classified into five 
categories (B1 to B5b) based on their potential malignancy (Table 1.4). 
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Table 1.4 Classification based on percutaneous breast biopsy established by the Royal College 
of Pathologist. Adapted from [34], [52]. 
 
Normal tissue (B1)  
Artefact, bleeding, microcalcification, … 




Columnar cell change 
Indeterminate lesions (B3) 
Atypical epithelial ductal proliferation (AEDIP) 
In situ lobular neoplasia, including lobular carcinoma in situ and 




Suspicious for malignancy (B4) 
Neoplastic cells contained within blood clots 
Very small foci of invasive carcinoma 
Non high grade intraductal proliferation with high degree of atypia 
Non-invasive cancer (B5a) 
Ductal carcinoma in situ (DCIS) and intracystic carcinoma 
Pleomorphic lobular carcinoma in situ (LCIS) 
Invasive cancer (B5b) 
Invasive ductal carcinoma (IDC) 
Invasive lobular carcinoma (ILC) 
Special type including papillary, tubular and mucinous carcinomas 
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This classification takes into account the histological features. Biopsies are classified 
as: normal (B1), benign (B2) or malignant (B5). However, some samples are difficult 
or impossible to classify in these groups and have their own categories (B3 and B4). 
The B3 category regroups usually benign lesions but sometimes their histology shows 
a risk of malignancy (e.g. atypical epithelial ductal proliferation or papillary lesion). The 
B4 category is not attributed to a specific pathology but for instance can be accredited 
to the procedure issues or containing artefacts with a potential carcinoma [52]. 
 
1.5.4. Consequences of the procedure 
 
Mammography and biopsy procedures are necessary steps to detect a pathology or 
refine a diagnosis but not without consequences for the patient. All women with 
mammographically suspicious lesions are recalled for further testing. If they do not 
have a malignant lesion, they have been subjected to unnecessary procedures, high 
risks of complication due to the procedure, emotional stress and anxiety. Only 10-25% 
of mammographically suspicious lesions are malignant [53]. Moreover, the cost of a 
false positive can be considerable for the NHS. For instance, in 2016, a standard 
needle biopsy and guides (i.e. marker clips) costed around £20 whilst a vacuum 
needle with guides around £300 [34]. Besides, it has to take into account the 
pathologist cost to prepare biopsies (embedded in paraffin, cut to a specific thickness, 
stained) and their analyses. 
 
1.6. Other procedures 
 
Different forms of biomedical imaging are the main tools for the detection of cancer at 
an early stage, evaluate the cancer progression, or response therapy, in real-time 
without tissue destruction. Many techniques are used for different purposes such as 
screening (i.e. mammography) or biopsy guidance (i.e. ultrasounds) [54] and are often 
supplementary to each other and adapted to the patient (often challenging in case of 
high breast density or obesity) [54]. 
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Breast imaging in routine screening  is based on X-ray mammography but other tools 
such as magnetic resonance imaging (RMI), tomography (i.e. positron emission 
tomography) or ultrasounds [54] are often used in breast cancer detection. 
Contrary to mammography, which uses X-rays, MRI is based on applying an external 
magnetic field. By using a contrast agent (i.e. gadolinium) [55], MRI has the ability to 
evaluate patients with a high breast tissue density, and can detect malignancy when 
it is difficult with mammography and also useful for patient with mammary implants 
[56]. Unfortunately, due to an expensive cost of the device, hospitals are not often 
equipped for MRI and, due to a high number of false positives, this technique is not 
used in the screening routine [54]. 
Positron emission tomography (PET) is based on the detection of radioactivity emitted 
by a radiopharmaceutical agent (often used 18Fluorodeoxyglucose or FDG) injected in 
the veins [57]. PET reflects metabolic changes and blood flow in the body. In contrast 
to X-ray or mammography, this technique evaluates the functionality and not the 
structure of breast [58], in particular by evaluating the rate of glucose consumption 
[57]. In fact, breast cancer is associated with an increase of glucose consumption in 
malignant lesions.  
Ultrasound can discriminate different tissues based on their elasticity according to the 
speed of propagation of the acoustic waves [54]. It has been proved that the elasticity 
of cancerous tissue is lower than that of normal tissue. Based on their elasticity and 
stiffness, breast tissues are discriminated between benign and malignant lesions [54], 
[56]. 
 
In parallel, imaging techniques i.e. ultrasound, MRI or positron emission 
mammography are also used to guide biopsy procedure [56]. 
 
The use of these techniques does not improve detection of microcalcifications in the 
breast, and their small size tends to challenge their recognition. Many studies evidence 
the ability of vibrational spectroscopy to identify chemical composition of 
microcalcifications in breast by using FTIR [59] and Raman spectroscopy [60]. Crystal 
powders of calcium Hap in tissue phantom could be also detected using a deep Raman 
instrument [61]. This, opens the possibility for the analysis of in vivo breast 
microcalcifications and could be used as a supplementary technique to mammography 
[62], [63]. 
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In a context of emergence of new tools for breast cancer screening, vibrational 
spectroscopy can help with the understanding and characterisation of specific 
changes in microcalcifications and therefore diagnose benign and malignant lesions. 
 
1.7. Vibrational spectroscopy 
 
1.7.1. Fourier Transform Infrared (FTIR) spectroscopy 
 
1.7.1.1. Principle of FTIR spectroscopy 
 
Vibrational spectroscopy is a family of non-invasive and non-destructive methods that 
are increasingly used in the analysis of biological samples such as tissues, cells and 
biofluids. Vibrational spectroscopy techniques detect the molecular composition and 
structure of a sample, based on the use of visible or infrared (IR) light to interrogate 
the vibrational modes of chemical moieties in molecules. In the case of IR absorption, 
by virtue of these vibrational modes, the molecules in a sample absorb IR light at 
certain frequencies and are promoted to excited vibrational levels. These energy 
transitions are different for different chemical groups in molecules, and hence an IR 
spectrum with patterns of signals at different frequencies is recorded. Using charts of 
known frequencies for specific functional groups, it is possible to assign the bands to 
particular types of vibrations, stretching or bending (Figure 1.23), of specific chemical 
bonds, e.g. O-H stretching (~3300 cm-1). Therefore, a vibrational spectrum is a 
chemical ‘fingerprint’ of a material and can be used to identify its molecular 
composition. It also provides a measure of the concentration of a sample based on the 
Beer-Lambert law: A= c l, where A is the absorbance at a given wavelength,  the 
molar absorption coefficient at that wavelength, c the molar concentration, and l the 
optical path length (thickness of the sample or cuvette size). 
 




Figure 1.23 Different types of vibrational modes of molecules. From Colombia University, New York. 
 
1.7.1.2. Quantum cascade laser (QCL) coupled to upconversion detector 
 
Developments including QCL and upconversion imaging approaches can make a 
transformation of the FTIR imaging technique from a benchtop to a rapid and sensitive 
tool for real-time screening. QCLs are semiconductor lasers constructed for the first 
time by Faist et al. in 1994 to perform hyperspectral imaging. Unlike FTIR 
spectroscopy with a Globar thermal source, which records the whole mid-infrared 
spectrum, QCL systems record images at a single frequency [64]. In fact, the system 
can be tuned to a particular wavelength range of interest, such as phosphate or 
carbonate regions in our case. If only a few discrete frequencies are required, this 
approach is faster than current FTIR spectroscopic imaging and focuses only on 
specific signatures, such as those from microcalcifications in breast cancer. Moreover, 
it has also been demonstrated that QCL systems can provide extremely fast scanning 
of large tissue areas when compared with FTIR imaging [64]. Another modification of 
standard spectroscopic approaches involves the use upconversion detection. 
Investigated in 1960s, upconversion imaging is based on replacing the hyperspectral 
imaging in the mid-IR using an FPA-MCT (Focal Plane Array-Mercury Cadmium 
Telluride) detector with a CCD (Charge-Coupled Device) camera. This technique 
proposes an alternative procedure using a non-linear crystal of lithium niobate that 
allows conversion of photons with a long wavelength into photons with a shorter 
wavelength that can be measured with a CCD camera [65]. The advantages of using 
a CCD camera is that it has a higher number of pixels (Megapixels) than the FPA-
MCT detector (128x128 pixels), does not require liquid nitrogen cooling and is cheaper 
to manufacture. 
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1.7.2. Raman microspectroscopy 
 
Raman spectroscopy is based on the inelastic scattering of light from matter, and 
vibrational Raman spectroscopy is sensitive to vibrational modes in molecules causing 
a change in polarizability (whilst IR absorption is sensitive to the modes causing a 
change in dipole moment, making the two techniques complementary for molecules 
with a centre of inversion). It is a scattering process whereby the molecule is promoted 
to a virtual state (Figure 1.24) from which it drops back to the same initial vibrational 
level (Rayleigh scattering) or to a higher (Stokes Raman) or lower (anti-Stokes 
Raman) level. In Raman microspectroscopy, a Stokes spectrum is measured where 
vibrational resonances correspond to frequency shifts in the mid-IR region, so the 
spectra from Raman and IR techniques can be compared and contrasted. 
 
 
Figure 1.24 Jablonski diagram showing the vibrational energy levels in molecules and the cases of 
elastic and inelastic light scattering. h0: incident photon energy, hvm: Raman shift or difference in 
vibrational energy between final and initial state. 
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1.7.3. Spectroscopy and clinical applications 
 
The important advantage of these vibrational techniques is that they are non-
destructive, label-free and chemically specific, providing molecular information about 
a sample. They can be applied in combination with microscopy, imaging approaches, 
and the use of probes to enable minimally invasive clinical applications. 
 
1.7.3.1. Breast tissue 
 
The potential for biomedical applications of these techniques has been demonstrated 
through several proof-of-concept studies [66]; in particular, Lyng et al. demonstrated 
that Raman microspectroscopy could be applied to breast cancer for discrimination 
between benign and malignant lesions [67]. Many studies show that vibrational 
spectroscopy can be used to analyse mineral components of bone and other calcified 
tissues and to identify the mineralisation [68]. In Raman microspectroscopy, the 
specific peak for Hap is at 960 cm-1 for phosphate and 1070 cm-1 for carbonate [37]. 
In FTIR spectroscopy, the peak positions are around 1020 cm-1 for phosphate and 
1410, 1450, 1423, 875 and 881 cm-1 for carbonate [59]. A few studies have focused 
on the analysis of breast microcalcifications. Haka et al. have demonstrated that 
Raman spectroscopy reveals differences in the chemical composition and structure of 
90 microcalcifications (from 11 patients) in the different types of lesions in the breast. 
In fact, the results of principal component analysis (PCA) show a larger amount of 
carbonate substitution in benign lesion, whilst a malignant lesion presents a higher 
content of proteins (by calculating the matrix-to-mineral ratio) [60]. Baker et al. have 
confirmed the previous results using FTIR spectroscopy and a cohort of 110 patients 
and 236 microcalcifications. They have also found that microcalcifications are 
separated into three distinct groups according to their carbonate and protein contents. 
In fact, malignant lesions present elevated protein and reduced carbonate level; vice 
versa benign lesions have reduced protein and elevated carbonate. The percentage 
of carbonate substitution has been found to be 2.08, 1.83 and 1.41% in benign, DCIS 
and IDC, respectively [59]. 
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Furthermore, a study led by Kerssens et al. using deep Raman spectroscopy in 
porcine tissue has demonstrated that it is possible to determine the level of carbonate 
substitution. This study shows that, in a thick layer of tissue, deep Raman can 
discriminate microcalcifications [37] and can be a good complement to the 
mammography screening. 
 
1.7.3.2. Cell mineralisation 
 
Several studies suggest that Raman microspectroscopy is a useful tool to assess in 
vitro mineralisation. Smith et al. have demonstrated that this technique provides 
specific information about early mineralisation (phosphate peak at 960 cm-1) in murine 
osteoblast calvarial cells. They were able to distinguish different precursors in Hap 
formation after three days of mineralisation [69]. Another study by E. Brauchle et al. 
confirms the previous results and shows a perfect discrimination between different 
stages of differentiation of MSCA-1+ JPCs using PCA [70]. Moreover, Raman 
microscopy was able to discriminate between two breast cancer cell lines (MCF-7 and 
MDA-MB-436) and normal breast cells (MCF-10a) [71]. These findings suggest that 
Raman microspectroscopy is capable to assess breast cancer mineralisation. 
 
1.8. Aims of the thesis 
 
This thesis aims to evaluate the chemical composition of microcalcifications in the 
mammary gland. It will explore different aspects of mineralisation in the breast, in 
particular using an in vitro approach of mineralisation or biopsy samples directly. This 
model of mineralisation is essential to understand the maturation process of the Hap 
crystal in a biological context and link the findings with the microcalcifications found in 
breast biopsy samples. For the first time, this work analyses the Hap crystal formation 
over time by using vibrational spectroscopy and evidences other actors involved in 
their formation. 
Furthermore, this work will explore novel spectroscopic methods to measure the 
composition of microcalcifications in breast tissue sections. In fact, for the first time, 
breast microcalcifications have been analysed in the long-wave infrared regime using 
upconversion detection combined with a QCL laser. The use of this unique setup may 
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have an impact on clinical translation of these approaches by allowing a selection of 
specific wavelengths of interest and also a simple detection using silicon based 
detectors more sensitive and cost efficient compared to MCT detectors commonly 
used in commercial systems. This may lead to a new diagnostic tool for identifying 
breast microcalcification changes during cancer progression. 
 
This thesis is divided into six chapters: Chapter 1 is a general introduction to breast 
cancer and microcalcifications. Chapter 2 is focused on the materials and methods. 
Chapters 3 to 6 are dedicated to the results, with a brief context of the study, relevant 
data and discussion. Chapter 7 is a general conclusion, which also covers future work. 
The themes of Chapter 3 to 6 are listed below: 
• Chapter 3 investigates different standard minerals typically found during the 
mineralisation process. It will focus on spectral characteristics of different 
components found in breast microcalcifications. 
 
• Chapter 4 examines breast biopsy samples using FTIR imaging and Raman 
microspectroscopy and comparison with the spectra of standard minerals. 
 
• Chapter 5 explores an in vitro model of breast cell mineralisation and compares 
its characteristics with those of standard minerals and breast biopsies. 
 
• Chapter 6 examines new IR technologies such as those based on QCL source 






Chapter 2 : Materials and Methods 
 
2.1. Sample collection 
 
2.1.1. Frozen tissue 
 
Female breast tissue samples were collected from the NIHR Exeter Clinical Research 
Facility at the Royal Devon and Exeter (RD&E) NHS Foundation Trust, under the 
tissue bank ethical approval (No 16/SC/0162). Samples were collected at the time of 
routine clinical care between 2011 and 2017 and the patients consented for research 
(see consent form in Appendix, supplementary data 1, Figure A.1). Samples were 
collected after surgery (mastectomy or wide local excision, WLE) and were tested by 
immunochemistry for ER and HER2 status. A total of 290 samples were stored at the 
tissue bank containing 145 biopsies taken at distance of the tumour (set considered 
as benign) and 145 taken in the tumour (set considered as malignant). The clinical 
data about the patients and the breast samples were collected by the hospital 
according to template for each patient. The form is illustrated in Appendix, 
supplementary data 1, Figure A.2. The age of patients is ranges between 41 and 96 
years. 
Amongst 145 breast cancer samples (malignant), only 16 samples contained 
microcalcifications after a reading under a microscope the consecutive H&E stained 
sections using an optical microscope with x4, x10 and x40 objectives in the lab. The 
sample size is around 5 mm diameter. Samples were classified according to their 
histological report: benign (n=1), DCIS (n=2), IDC (n=11), ILC (n=1) and mixed IC 
(n=1). For each sample, three adjacent sections were cut without cutting agent and 
mounted onto barium fluoride (BaF2) slides for Raman and FTIR imaging analysis, and 
one stained with H&E for histological analysis, i.e. the “gold standard” for diagnosis. 
Each section was 5 μm thick. The sections were stored at -80°C prior to the 
spectroscopic analysis. For clarity, the protocol is summarised in Figure 2.1a. 
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2.1.2. Paraffinised tissue 
 
Two batches of paraffinised breast cancer tissue were collected for this study. Dr 
Renzo Vanna from the Insituti Clinici Scientifici Maugeri in Pavia, Italy, provided the 
first batch of 11 samples. They were classified according to the degree of pathology 
into: benign (n=5) and malignant, including DCIS (n=5) and IDC (n=1) with 
microcalcifications. Three adjacent sections embedded in paraffin were prepared: one 
(3 µm thick) was mounted onto a BaF2 slide for FTIR analysis, one (10 µm thick) 
mounted onto stainless steel for Raman, and the last one was mounted onto a glass 
slide and stained with H&E. 
The second batch of 13 samples with microcalcifications was previously collected from 
the Gloucestershire Royal Hospitals NHS Foundation Trust. As the other batch, 
samples were classified and analysed according to the degree of pathology: benign 
(n=5), DCIS (n=5) and IDC (n=5) lesions with microcalcifications. For each sample, 
two adjacent sections of 3 µm thickness were analysed: two sections mounted onto a 
BaF2 slide for FTIR and QCL spectroscopy analysis and one section mounted on a 




Figure 2.1 Experimental protocols used for the preparation of biopsy tissue samples for FTIR and 
Raman microspectroscopy measurements. 
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2.1.3. Mineral standards 
 
Prof. Mary Tecklenburg from Central Michigan University, USA, generously provided 
home-made B-type cHap powders. These standards were made by incorporating 
different levels of CO32- (1.24, 2.92, 4.43, 5.24, 7.52 and 8.12 wt.%) in the Hap lattice 
as part of the synthesis process. In parallel, pure Hap powder (97% pure, Sigma-
Aldrich) was used to perform a calibration curve. 
Another set of standards was generously given by Prof. Keith Rogers from Cranfield 
University: Amorphous Calcium Phosphate (ACP), Octacalcium Phosphate (OCP) 
and β-Tricalcium Phosphate (β-TCP). 
 
2.1.4. Breast cancer cell line 
 
The human MDA-MB-231 cell line, which is a highly invasive metastatic cell line 
obtained from an adenocarcinoma in the mammary gland, was used in this study. This 
sample was a gift from Dr Maria Morgan at the Royal College of Surgeons in Ireland 
(RCSI). Cells were stored in sterile cryovials kept in liquid nitrogen prior to the 
experiments. The procedure of cell culture and the mineralisation induction are 




2.2.1. Raman microspectroscopy 
 
Micro-Raman measurements were acquired using a Renishaw inVia confocal Raman 
microscope, comprising a 50x long working distance objective (N.A. 0.5) for 
illumination and for collection of the backscattered light, xyz motorized stage, 600 
lines/mm grating and CCD camera (Figure 2.2). The excitation beam was from a NIR 
diode laser source with 830 nm wavelength. 
 




Figure 2.2 (a) Raman confocal microscope coupled to a spectrometer and CCD camera. (b) Diode 
laser source at 830 nm used in these measurements. (c) Schematic diagram of the Raman setup. Red 
line: laser beam. Blue line: scattered light (Stokes part) dispersed by the grating and detected by the 
CCD camera. 
 
Before each set of measurements, a system calibration was performed using three 
standards: silicon wafer, neon-argon lamp and green glass. 
 
2.2.2. IR microspectroscopy 
 
All samples were measured using an Agilent 670 FTIR spectrometer, containing a 
Michelson interferometer (Figure 2.3) and coupled to an Agilent 620 FTIR microscope 
equipped with both 4x and 15x Cassegrain objectives and an MCT-FPA detector 
(128x128 pixels). 
 




Figure 2.3 (a) Agilent Cary 670 FTIR spectrometer coupled to an Agilent Cary 620 FTIR 
microscope. (b) Schematic diagram of a Michelson interferometer. The IR beam is separated in two by 
a beam-splitter, one beam is sent to a fixed mirror and the other one to a moveable mirror so that a 
path length difference is introduced. When the beams recombine at the beam-splitter, an interferogram 
is produced which contains all wavelengths from the source at once. As the light travels across the 
sample, some wavelengths are absorbed owing to vibrational modes of molecules in the material. A 
background and sample measurements are performed in succession to ensure minimisation of any 
absorption of IR light arising from the environment and optical setup. A mid-IR spectrum of the sample 
is then obtained and plotted for analysis [72]. 
 
2.2.3. QCL system coupled to upconversion detector 
 
IR measurements were also conducted using a lab-built QCL system developed by 
Pedersen et al. from the Denmark Technical University. It is composed of three parts: 
a QCL source, a microscopy unit and an upconverter unit (Figure 2.4). 
The QCL source was used as long-wavelength infrared (LWIR) source, widely 
tuneable within the range 9.34 to 12 µm. In this setup, the QCL beam is focused by a 
lens to a spot of approximately 82 μm diameter (spatial resolution) onto the sample 
which is located on a microscope stage. The transmitted light is coupled to a mixing 
source (Near-infrared, NIR) which is a diode-pumped 1064 nm laser operating in 
continuous wave which generates an average power of up to 3 W. These combined 
laser (LWIR and NIR) beams are focused into a nonlinear crystal (AgGaS2), which is 
the up-converter unit. At the end, a NIR signal is detected by a silicon power meter. 
 




Figure 2.4 Schematic diagram of the experimental setup comprising a QCL source, a motorised 
xy microscope stage, mixing laser, nonlinear crystal and silicon power meter, [73]. 
 
The upconverted images obtained are in false colours, where red corresponds to high 




2.3.1. Raman analysis of mineral standards 
 
For the Raman measurements, standards were analysed in their powder form on 
calcium fluoride (CaF2) substrates using the parameters listed in Table 2.1 
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Table 2.1 Raman parameters for the analysis of mineral standards, breast tissue sections and 
breast cancer cells. 
 
 
Ten spectra were recorded for each mineral with 5 s exposure time and 5 
accumulations using WiRE software. Two replicates were performed. 
 
2.3.2. Raman mapping of tissue samples 
 
2.3.2.1. Frozen tissues 
 
A micro-Raman map of each sample which contained microcalcifications was 
recorded using the streamline mode of the Renishaw inVia microscope, as 
summarised in Table 2.1. The acquisition time was 15 s with a step size of 1.4 µm. 
Raman maps were recorded using WiRE software. 
 
2.3.2.2. De-paraffinised sections 
 
A de-paraffinisation procedure was performed before the Raman mapping 
measurement to prevent artifacts due to the strong contribution of paraffin in Raman 
spectra. Samples were deparaffinised using a protocol suggested by Dr Vanna 
involving consecutive washing: 
- Two baths of 95% hexane for 5 minutes 
- Two baths of 100% ethanol for 5 minutes 
- One bath of 95% ethanol for 5 minutes 
- Slides are air-dried at room temperature overnight. 
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Biopsies were analysed using the following parameters: a map of each sample with 
microcalcification areas was recorded using streamline mode, with an 830 nm diode 
laser source at 100% laser power, a grating of 1200 lines/mm and centred to 1250 cm-
1. The acquisition time was 3 s with a step size of 8.4 µm and a bin of 6. Raman maps 
were recorded using WiRE software. 
 
2.3.3. FTIR analysis of mineral standards 
 
Pellets of minerals were prepared according to the following protocol: 99 mg of KBr 
powder was added to 0.5 mg of cHap, mixed and grounded together to a fine powder 
using a mortar and pestle. The mixture was transferred into a manual hydraulic press 
(Specac) and compressed for 1 h with a pressure of 10 t. In order to be analysed by 
FTIR spectroscopy in transmission mode, each pellet should contain the appropriate 
amount of sample so that the IR light is not fully absorbed. For the background 
spectrum, a pellet containing only 100 mg of KBr (transparent) was also prepared. The 
KBr/cHap pellets were analysed in single-point spectrum mode. Spectra were 
recorded in the spectral range comprised between 4000 and 700 cm-1 with a spectral 
resolution of 4 cm-1. Each spectrum was obtained by averaging 32 scans, whilst the 
background spectrum was recorded with 64 scans. Spectra were collected using 
Agilent Resolutions Pro software. Five spectra were recorded for each sample. Two 
replicates were performed. 
 
2.3.4. FTIR analysis of tissue samples 
 
A map of each sample with microcalcification areas was recorded using the Agilent 
FTIR imaging system. The parameters are listed in Table 2.2. A background spectrum 
was recorded using a clean area of BaF2 for each sample. 
Biopsies were also analysed in single-point mode and the parameters are summarised 
in Table 2.2. Five spectra were recorded for each sample and collected using Agilent 
Resolutions Pro software. 
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Table 2.2 FTIR parameters for the analysis of biopsy samples, frozen and paraffinised tissue. 
 
 
2.3.5. QCL analysis of mineral and biological samples 
 
Pellets of standards (as previously described in section 2.3.3) and paraffinised 
biopsies were analysed with the same parameters as the breast tissue samples using 
the QCL system described previously (section 2.2.3). 
Spectra were recorded in the spectral range comprised between 1066 and 830 cm-1, 
with a spectral resolution of 4 cm-1. Background (pure KBr pellet) and cHap spectra 
were recorded at each discrete wavenumber. In these conditions, five spectra were 
recorded for each sample. 
 
2.3.6. Analysis of breast cancer cell mineralisation 
 
2.3.6.1. Induction of cell mineralisation 
 
Before the study, MDA-MB-231 cells were maintained in sterile 75 cm2 flasks with a 
standard growth media of DMEM (Thermofisher Scientific) supplemented with 10% of 
foetal bovine serum (FBS, Thermofisher Scientific) and 1% Penicillin/Streptomycin 
(Thermofisher Scientific) at 37°C and 5% CO2 atmosphere in an incubator for few 
days. After removing the media, cells were trypsinised (Thermofisher Scientific) and 
washed with PBS. Cells were seeded at 0.8 x 106 cells/well in 3 mL/well of media 
(DMEM and FBS) within 6-well plates. Cells were grown overnight at 37°C, 5% CO2 
onto calcium fluoride (CaF2) slides inserted into the 6-well plates. The next day (day 
1), the mineralisation was induced by two pathways using different osteogenic agents 
(Figure 2.5). The first pathway consists of adding an osteogenic cocktail (OC) coupled 
to Dexamethasone (Dex) (Sigma Aldrich, D4902) to the media. The OC is composed 
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of β-glycerophosphate (βG) (Sigma Aldrich, 50020), which is a source of inorganic 
phosphate, and ascorbic acid (AA) (Sigma Aldrich, 49752), which promotes collagen 
production. Dex is considered an inducer of osteoblastic differentiation. The second 
pathway uses Pi directly into the media, coupled with Dex, to induce faster 
mineralisation (Figure 2.5). 
 
 
Figure 2.5 Protocol for mineralisation of the MDA-MB-231 cell line using different osteogenic 
agents. βG: β-glycerophosphate, AA: ascorbic acid, Dex: Dexamethasone, Pi: inorganic phosphate. 
 
Osteogenic agents (βG, AA and Dex) were added to 3 mL/well of media at different 
concentrations (Table 2.3). Pi was also added to 3 mL/well of media but prepared from 
Na2HPO4 + NaH2PO4 (Sigma Aldrich S5136, 71496) powders in a 4:1 molar ratio as a 
1 M stock solution. The solution was diluted in pyrogen-free water (Thermofisher, 
H20CC0106). Solutions of osteogenic agents were prepared in advance, divided in 
aliquots and kept at -80°C for further experiments. Media were changed every three 
days. 
 
Table 2.3 Concentrations of osteogenic agents employed to induce mineralisation. βG: β-
glycerophosphate, AA: ascorbic acid, Dex: Dexamethasone, Pi: inorganic phosphate. 
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The mineralisation process was stopped at day 3, 7, 11 and 14 (Figure 2.6) and the 
samples were analysed using IR and Raman microscopy. Cells were washed three 
times with PBS, fixed with 4% paraformaldehyde (Thermofisher Scientific, A11313) for 
30 minutes and air-dried at room temperature. In parallel, cells were grown onto CaF2 
substrates submerged in 6-well plates using regular growth media and fixed on the 
same days. Three replicates were performed in this study. 
 
 
Figure 2.6 Illustration of the mineralisation process for each condition (Control: only DMEM), OC 
and Dex, and Pi and Dex. Cells were fixed at day 3, 7, 11 and 14. 
 
2.3.6.2. Raman mapping of breast cancer cells 
 
Raman maps of different areas of mineralised cells at specific days of mineralisation 
(Day 3, 7, 11 and 14) were recorded using streamline mode, and the parameters are 
summarised in Table 2.1. The acquisition time was 30 s with a step size of 9 µm and 
a bin of 7. 
 
2.3.6.3. FTIR imaging of breast cancer cells 
 
FTIR maps of different areas of mineralised cells at specific days of mineralisation 
(Day 3, 7, 11 and 14) were recorded using a spectral resolution of 4 cm-1 and a spatial 
resolution of 5.5 µm/pixel with x15 objective. Spectra were acquired over a spectral 
range comprised between 3800 and 900 cm-1. Each spectrum was obtained by 
averaging 256 scans, and a background spectrum was also recorded with 512 scans.  
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2.4. Data analysis 
 
2.4.1. Selection of spectra 
 
Datasets were analysed using a home-made program in Matlab software (Mathworks, 
USA). Spectra were selected from a central location within the microcalcification in 
Raman maps and IR images based on the phosphate peak intensity at 960 cm-1 and 
1030 cm-1, respectively. 
 
2.4.2. Peak decomposition analysis 
 
Curve fitting analysis of spectral band shapes was performed using OriginPro software 
(OriginLab, USA). A mix of Gaussian and Lorentzian functions were used to fit the 
FTIR and Raman spectra in different carbonate and phosphate regions. The 
Levenberg-Marquardt algorithm was used to minimize the 𝜒2 value. The peak 
positions were fixed whilst the peak widths were free fitting parameters. 
A mean spectrum was calculated from ten spectra of each sample (mineral standards, 
cells or biopsies). Raman spectra were truncated in the spectral range of interest for 
phosphate (985-900 cm-1) and carbonate (1100-1010 cm-1) bands. IR spectra were 
truncated in the spectral range 1200-900 cm-1 for phosphate and 890-830 cm-1 and 
1480-1330 cm-1 for carbonate bands. Raman spectra were smoothed with the 
Savitzky-Golay algorithm, second polynomial order with 9 points, using OPUS 
software (Bruker Optics, Ettlingen, Germany). A baseline correction using the rubber-
band method with 64 data points was also performed on each spectrum. After baseline 
correction, a second derivative was calculated for each IR spectrum to identify sub-
band positions to be used in the curve fitting analysis. 
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2.4.3. Principal Component Analysis (PCA) 
 
PCA is a method that has proved capable of discriminating small variations between 
spectra contained in large datasets. It is an unsupervised classification method which 
simplifies a complex dataset by reducing the number of variables and removing all 
redundancy in the information. The new dataset is divided in principal components 
(PC 1, 2, 3 …) and classified according to the importance of information in the dataset 
[74]. PCA was applied to the spectra and maps using a home-made program written 
in Matlab (Mathworks, USA). 
 
2.4.3.1. PCA applied to set of single spectra from FTIR and Raman maps 
 
In this analysis, PCA classifies information in groups by producing a cloud of points 
according to PCs. Each point corresponding to a spectrum. Spectra from the in vitro 
mineralisation study were selected for each sample (as described in Section 1.4.1), 
and then a PCA was performed on both Raman and IR spectra. Prior to PCA, Raman 
spectra were smoothed (Savitzky-Golay algorithm, second polynomial order, 9 points), 
and baseline corrected using OPUS software (Bruker Optics, Ettlingen, Germany). 
Owing to a strong scattering background in the IR spectra, Mie scattering correction 
was performed accordingly to A. Kholer’s program in Matlab. In fact, when the IR light 
goes through a scattering particle (e.g. microcalcification), its path is deviated, which 
induces consequences in FTIR spectroscopy. The IR spectra, containing the 
biochemical information are distorted and the analysis is challenging. In consequence 
of which, a Mie scattering correction is applied before the processing  [75], [76]. It is 
an algorithm, which corrects distortion in spectra based on the extended multiplicative 
signal correction (EMSC). In this correction, a target spectrum of Matrigel, which 
contains pure proteins of the ECM [76], was used to reproduce the baseline. Then, 
spectra were truncated in the spectral region between 1800 and 900 cm-1. 
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2.4.3.2. PCA applied to Raman and IR maps 
 
Prior to applying a PCA to Raman spectra, a cosmic ray removal was performed by 
using a median filter, followed by a baseline correction with asymmetric least squares 
smoothing and a vector normalisation in Matlab, whilst IR spectra were truncated to 
the fingerprint region (1800-900 cm-1) and vector normalised (Matlab). A PCA was 
performed on Raman and IR maps of breast tissue samples using a toolbox in Matlab. 
 
2.4.4. Partial Least Square (PLS) model 
 
PLS is a supervised method which identifies the relationship between several 
variables [77]. In the context of the measurements presented here, the model was built 
to be able to determine the amount of carbonate within microcalcifications in breast 
tissue biopsies based on spectral analysis performed with the different mineral 
standards. The advantage of using this model is that it takes into account the statistical 
variance, e.g. variation between the concentration (carbonate ion substitution) given 
by the manufacturer and the real percentage of carbonate in the Hap powders or the 
variation between biopsies from different patients or different stages of pathology [77]. 
The PLS model was performed using a program in Matlab software (Mathworks, USA). 
The aim was to use a model spectrum based on the cHap standards in order to obtain 
the most relevant information also called latent factors or variables. The next step was 
to decompose the dataset from breast tissues to extract the relevant information that 
fit the model spectrum. The PLS model was built for a given number of latent factors 
and then used to predict the percentage of carbonate ion substitution in each 
microcalcification contained in breast tissue sections [78]. Raman and IR spectra were 
truncated to the phosphate and carbonate region, as described before. Raman spectra 
were baseline corrected and normalised in Matlab. FTIR spectra were normalised and 











As discussed previously, mineralisation is a complex mechanism which occurs in 
normal physiology in bone formation or bone remodelling but also in pathological 
processes, e.g. vascular calcifications, urinary stones, mammary microcalcifications 
etc. It appears that mineralisation found in different diseases is not defined as a linear 
process, but instead is complex and composed of different phases. The timeline and 
different stages of mineralisation for breast microcalcifications are still unknown. 
 
3.1.1. Mineral phase and precursors 
 
The mineral phase of a normal calcification corresponds to the formation of cHap 
crystal and is considered as the main compound of calcifications [79]. However, many 
studies suggest that different components are involved during this mineral phase. In 
fact, different calcium phosphates are considered as playing a role in cHap formation 
[80], such as amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), 
dicalcium phosphate dehydrate (DCPD), or tricalcium phosphate (β-TCP) [40], [80], 
[81]. A few examples of phosphate minerals occurring in biological tissues with their 
chemical formula are listed in Table 3.1. 
Following the example of Hap crystal, which is not found in its pure form but 
carbonated, β-TCP is not pure but always magnesium-substituted (β-TCMP) in 
biological tissue [82]. 
  
Chapter 3 : Mineral standards as a model for microcalcifications 
57 
 
Table 3.1 Phosphate minerals in biological human tissues. In cHap, x = other cation substitutions 
for Ca2+ and y= other anion substitutions for OH-. In ACP, the calcium-to-phosphate ratio is variable. 
Adapted from [40], [80]–[82]. 
 
 
These elements are involved in several physiological or pathological processes such 
as bone formation or vascular calcifications [83]. A study has reported the case of a 
dog with dental calculus containing mainly calcium carbonate (or calcite), which is not 
the case in human where OCP is mainly found. The conclusion was that the dog saliva 
has a higher pH than human and could be responsible for calcite formation [80]. 
Hence, pH variation can also interfere with the mineralisation process. 
Finally, depending on pH variation or temperature, these different elements of the 
mineral phase can contribute to the transformation of one compound into another, e.g. 
OCP or ACP can transform into cHap and cHap into ACP or β-TCP [80], and the 
question here is whether these results can correlate with the onset of a tumour. 
 
3.1.2. Tumour environment and calcifications 
 
Tumours are known to induce hypoxia and upregulation of metabolic processes. 
Changes in metabolic activity lead to an increase of H+ and CO2 intracellular 
concentrations which are released (via different transporters) out of the cells creating 
an acidic environment [84]. This phenomenon has been observed in breast cancer 
progression. In fact, in normal breast ducts, the extracellular pH (pHe) and intracellular 
pH (pHi) are 7.4 and 7.2, respectively, which correspond to a physiological pH. 
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Conversely, in DCIS, the pHe decreases to 6.8 and 6.7 for invasive stage, whilst the 
pHi remains stable around 7.2 in both stages. The regulation of tumour pH plays an 
important role in cell proliferation and cancer progression [85]. 
Thus, the acidic environment created by tumour can involve different precursors in 
microcalcifications. In this study, the hypothesis is that different elements found in 
breast tissue biopsy samples can be associated with cHap but also with other 
components (e.g. OCP, ACP). Hence, a spectroscopic analysis of minerals other than 
cHap is appropriate in order to determine the composition of microcalcifications in 
human tissue samples. 
 
3.2. Spectroscopic analysis 
 
Many studies have previously used FTIR and Raman spectroscopy techniques to 
readily analyse biological apatite and in particular the carbonated apatite mainly found 
in biological samples, e.g. bone, dental enamel [36], [86]. For instance, using these 
complementary techniques, it is possible to assess the contribution of each component 
of mineral standards (phosphate and carbonate groups) separately. In fact, PO43- and 
CO32- ions present both IR- and Raman-active modes [87]. 
 
 
Figure 3.1 Vibrational modes of (left) PO43- ion and (right) CO32- ion. Modified from [87]. 
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As illustrated in Figure 3.1 (left), phosphate ions have four distinct vibrational modes: 
1 and 3 corresponding to the symmetric and asymmetric stretching, respectively, 2 
and 4 corresponding to the symmetric and asymmetric bending, respectively. Note 
that stretching is related to a change in bond length whilst bending is related to a 
change in bond angle [87]. These vibrational modes are active both in Raman and IR 
spectroscopy. 
Carbonate ions (Figure 3.1 right) have also four vibrational modes: 1 and 3 
corresponding to the symmetric and asymmetric stretching, respectively, 2 and 4 
corresponding to the out-of-plane and in-plane bending, respectively. 1 is the only 
Raman-active mode, whilst 2, 3 and 4 are the IR-active modes (mutual exclusion 
rule) [87]. 
 
Based on this knowledge, the starting point of the study was to identify the peaks 
related to phosphate and carbonate ions and assess their position. 
 
3.2.1. FTIR and Raman spectra of cHap powders 
 
Mineral standards (as presented in Chapter 2, section 2.1.3) were analysed using 
FTIR and Raman spectroscopy. A number of peaks (PO43- and CO32- bands) and their 
positions were assessed based on published tables in the literature in order to interpret 
data from biopsy samples and in vitro microcalcifications. 
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3.2.1.1. Raman spectra 
 
Figure 3.2 Raman spectra from Hap pellets containing an increasing percentage of CO32- 
substitution: (a) 1.24%, (b) 2.92%, (c) 4.43%, (d) 5.24%, (e) 7.52% and (f) 8.12% w/w. The spectra 
exhibit specific PO43- and CO32- bands of interest. Each spectrum was obtained as an average of 5 
spectra per mineral. Spectra were normalised to the overall intensity in the range 1800-350 cm-1. 
 
Figure 3.2 shows an example of Raman spectra in the fingerprint region from Hap 
containing different percentage of CO32- substitution. Raman spectra exhibit several 
PO43- and CO32 bands. Based on data from Penel et al., the peak at 1072 cm-1 was 
assigned to the 1 CO32- band whilst all the other peaks are related to different 
vibrational modes of the PO43- ion [36]. The 1 CO32- band is well-defined and appears 
to increase proportionally to the increasing amount of CO32- substitution. The peak 
assignment is reported in Table 3.2. 
The PO43- band at 961 cm-1 is the most known and used in several studies, for instance 
to determine the crystallinity of Hap or to calculate the amount of carbonate. Penel et 
al. have highlighted that, based on this peak, it is possible to discriminate between 
type A and type B CO32- ion substitutions [36]. In fact, in type A substitutions, the 
phosphate peak presents two peaks at 947 and 957 cm-1 which is not the case in our 
cHap powders. Regarding the CO32- band, discrimination is also possible with two 
peaks at around 1103 and 1070 cm-1 for type A and B, respectively. Only one peak at 
1072 cm-1 is apparent in our samples. These results demonstrate that our samples 
contain only type B CO32- ion substitution. 
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In parallel, pure hydroxyapatite without carbonate substitution was also analysed and 
compared with cHap in order to distinguish the main changes in the Raman spectra 
due to carbonation (See Appendix, supplementary data 2, Figure B.1). The 
comparison between pure Hap and the different cHap spectra shows the same 
position for all the phosphate peaks. However, an additional peak at 1076 cm-1 is 
observed in pure Hap spectra, which corresponds to 3 PO43- band. No carbonate 
bands are apparent in pure Hap spectra. 
 
3.2.1.2. FTIR spectra 
 
The same investigation was performed using FTIR spectroscopy. Figure 3.3 shows an 
example of FTIR spectra in the fingerprint region from KBr pellets of Hap containing 
different percentage of CO32- substitution. 




Figure 3.3 FTIR spectra from Hap pellets containing an increasing percentage of CO32- 
substitution: (a) 1.24%, (b) 2.92%, (c) 4.43%, (d) 5.24%, (e) 7.52% and (f) 8.12% w/w. The spectra 
exhibit specific PO43- and CO32- bands of interest. Each spectrum was obtained as an average of 5 
spectra per mineral. Spectra were normalised to the overall intensity in the range 1800-700 cm-1. 
 
For clarity, spectra were normalised and stacked (See appendix, supplementary data 
2, Figure B.2 for the full spectral range). Four specific peaks are well-defined and 
correspond to 1 and 3 PO43- bands and 2 and 3 CO32- bands. In particular, for the 
3 PO43- band, which is a broad peak, the shape seems to vary with the amount of 
carbonate. A shoulder at 1097 cm-1 appears in the lowest concentrations of carbonate 
at 1.24 and 2.92 wt.% (a and b, blue and red spectra) and disappears slowly from 4.43 
to 8.12 wt.% of CO32- substitution (Fig. 3.3c-f). The 2 and 3 CO32- bands are also 
well-defined and appear to increase proportionally to the increasing amount of CO32- 
substitution.  
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FTIR spectra exhibit numerous PO43- and CO32- bands. When comparing with 
literature, it appears that three peaks correspond to CO32- bands at 1450 and 1423 
cm-1 and one at 874 cm-1. Two peaks at 962 and 1031 cm-1 are PO43- bands [88], [89]. 
The assignment for each peak is summarised in Table 3.3. 
 
Table 3.3 Assignment of peak positions for PO43- and CO32- bands for cHap samples based on 
the literature, [88]–[90]. 
 
 
Based on these results, it is also possible to distinguish type A from type B CO32- ion 
substitution. In fact, for type B, two peaks are found between 1450-1456 cm-1 and 
1422-1427 cm-1 for 3 CO32- and 875 cm-1 for 2 CO32-. For type A substitution, three 
peaks are found at 1545, 1450-1456 cm-1 for 3 CO32- and 880-881 cm-1 for 2 CO32- 
[88]. In our cHap standards, only type B CO32- ion substitution is found which is in line 
with the results obtained from Raman spectra. However, further analysis needs to be 
performed e.g. area under each peak, calculation of carbonate-to-phosphate ratio etc. 
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3.2.2. Raman and FTIR spectra of other standards 
 
In order to complete the study, additional minerals were analysed using Raman and 
FTIR spectroscopy. Spectra of ACP, β-TCP and OCP, which are considered potential 
precursor phases, were recorded. Raman and FTIR spectra are shown in Figure 3.4 
and 3.5, showing peak positions and their corresponding assignment to PO43- and 
CO32- modes. 
Regarding the Raman spectra (Figure 3.4), the peaks correspond to different 
vibrational modes of the phosphate group. ACP exhibits five peaks: 
- 1 PO43- band at 955 cm-1 (with an upshift of 4 cm-1 to the peak previously found) [91], 
[92]. 
- 3 PO43- bands at 1034 and 1077 cm-1 (instead of a single peak at around 1050 cm-
1) [91]. 
- 4 PO43- band at 588 cm-1 and 2 PO43- band at 427 cm-1 as expected. 
Unfortunately, the literature is quite poor and contradictory regarding the Raman 
analysis of ACP. The shift and additional peaks could be due to the sample 
preparation, which depends greatly on temperature and preparation time [92]. 
The spectrum of β-TCP presents nine peaks (1088, 1015, 969, 949, 630, 548, 476, 
438 and 407 cm-1) [91], [93] and OCP eight peaks (1077, 1046, 1011, 958, 874, 609, 
590, 427 cm-1) [91], [94], [95] corresponding to the different vibrational modes for PO43- 
ion which are expected and in line with other publications. 
 
The FTIR spectra of ACP (Figure 3.5) exhibit four peaks corresponding to PO43- and 
CO32- modes: 1 PO43- band at 1059 cm-1 [96], 3 CO32- bands at 1427 and 1483 cm-1, 
and 2 CO32- band at 873 cm-1 which seems to arise from type B CO32- ion substitution. 
The spectrum of β-TCP exhibits seven peaks [91], [97] and OCP five peaks [91], [95] 
corresponding to as many PO43- modes. All peak positions are in line with the 
literature. 




Figure 3.4 Raman spectra of (a) ACP, (b) β-TCP and (c) OCP powders. Average of 5 spectra. 
Spectra were baseline-corrected to 2200-350 cm-1. 




Figure 3.5 FTIR spectra of KBr pellets from (a) ACP, (b) β-TCP and (c) OCP. Average of 5 spectra. 
Spectra were normalised to 1800-700 cm-1. 
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3.3. Peak analysis 
 
To analyse the phosphate and carbonate bands of the minerals, a peak decomposition 
by curve fitting analysis was applied to the spectra. This method allows us to single 
out overlaid peaks and to extract the area and full width at half maximum (FWHM) for 
each peak. These data are then used to calculate the carbonate-to-phosphate (C:P) 
ratio for each sample. A study from Gadaleta et al. suggests using as a reference, the 
results from the second derivative analysis (for the FTIR data), to enable sub-peak 
positions to be appropriately identified and correlated with the curve fit analysis [98]. 
The results from the peak decomposition for each sample’s FTIR and Raman spectra 
are shown in Appendix, supplementary data 2, Figure B.3–B.8. 
 
 
Figure 3.6 Results of curve fit analysis applied to (a, b) FTIR and (c, d) Raman spectra of cHap 
containing 2.92 wt. % CO32- substitution. Spectra were truncated to (a, c) phosphate band (1200-900 
cm-1) and (b, d) carbonate band (890-855 cm-1) and baseline-corrected. R2 > 0.99. 
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Figure 3.6 illustrates the results of peak decomposition applied to FTIR and Raman 
spectra for each CO32- and PO43- band separately. The peak decomposition gives 
information about the sub-bands in FTIR and Raman spectra. All FTIR spectra from 
cHap pellets present the same profile with nine components (1117, 1098, 1086, 1072, 
1060, 1046, 1018, 1032 and 962 cm-1) for PO43- except for cHap 5.24% and 8.12% 
CO32-: one additional peak at 1002 cm-1 for 5.24% cHap and one missing at 1072 cm-
1 for 8.12% cHap substitution (see Appendix, supplementary data 2, Figure B.3). 
Regarding the CO32- band, all cHap are well-represented by four components at 
around 880, 873, 866 and 861 cm-1. 
The peak positions and their assignments are summarised in Table 3.4. 
 
Table 3.4 FTIR peak positions and their assignments to the phosphate and the carbonate bands 
of cHap based on the literature, [86], [88], [89], [98]–[102]. 
 
All listed peak positions correspond to different vibrational modes of CO32- and PO43- 
and are in line with the literature [86], [88], [89], [98]–[102]. 
To determine the sub-bands in FTIR spectra, the results were combined with those 
derived from the second derivative spectra. The correlation between the second 
derivative results (Figure 3.7) and the peak decomposition show a good agreement in 
terms of number and position of the peaks. 




Figure 3.7 Second derivative spectrum of cHap pellet with 2.92 wt. % CO32- substitution. 
 
In parallel, a peak decomposition was also performed for the carbonate band at 1500-
1400 cm-1 in order to select the best carbonate peak for a calibration curve. 
As illustrated in Figure 3.8, FTIR spectrum exhibits five components at around 1495, 
1466, 1453, 1441 and 1419 cm-1 corresponding to a combination of the 1 CO32- band 
[88]. All the FTIR spectra exhibit the same five components (data not shown).  
 
 
Figure 3.8 Results of a peak decomposition performed on the FTIR spectrum of cHap with 2.92 
wt. % CO32- substitution. The spectrum was baseline-corrected to 1400-1520 cm-1. R2 > 0.99. 
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Regarding the Raman spectra, the same analysis was performed and illustrated in 
Figure 3.6 (see above). cHap spectra exhibit the same profile for PO43- and CO32- 
bands. There are two components at around 945 and 960 cm-1 for the PO43- band. For 
the CO32- band, six components are present for each sample: 1029, 1040, 1047, 1061, 
1070, and 1076 cm-1, where 1070 cm-1 corresponds to the 1 CO32- mode at 1070 cm-
1 [103]. The peak positions and their assignments are listed in Table 3.5. 
 
Table 3.5 Raman peak shifts and their assignments to the phosphate and carbonate modes of 
cHap based on the literature, [36], [103]. 
 
 
The area and FWHM of each peak (from FTIR and Raman spectra) are summarised 
in Appendix, supplementary data 2, Table B.1–1.6. 
A peak decomposition analysis was also applied to the spectra of the other minerals 
including ACP, OCP and β-TCP. Common peaks to cHap were found in these minerals 
based on both FTIR and Raman data (see Appendix, supplementary data 2, Figure 
B.5 and B.8). 
 
3.4. Calculation of the C:P ratio 
 
The aim of this study was to derive a calibration curve, based on the results from curve 
fitting analysis, to assess the carbonate content of microcalcifications in breast tissue 
biopsy sections. The C:P ratio was calculated based on peak areas for each cHap 
sample to which a given amount of carbonate substitution (provided by the 
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manufacturer) was associated. This calculation was performed for both Raman and 
FTIR spectra in order to validate the method. 
 
3.4.1. Analysis of FTIR spectra from cHap pellets 
 
 
Figure 3.9 Linear regression of the plot of C:P ratio vs. % CO32- substitution in cHap pellet samples. 
Data were obtained from FTIR spectra as the ratio of the peak area at 875 cm-1 to the sum of all 
phosphate peak areas. Two replicates were performed in those experiments. Values are mean ± SD. 
Regression equation: y = 7.42·10-4 x; R2 = 0.97. 
 
The lack of information regarding the optimal definition of C:P ratio to use for FTIR 
analysis makes it challenging to extract a calibration curve, and hence different 
combinations were tested. Firstly, a calibration curve was performed based on the 
ratio of the 875 cm-1 peak area for carbonate peak to the total phosphate peak area. 
From this calculation, the quantitative relationship between the CO32-/PO43- peak area 
ratio and the amount of CO32- in each cHap was established by linear regression with 
a high correlation coefficient (R2 = 0.97) as illustrated in Figure 3.9. Secondly, different 
C:P ratios were calculated e.g. based on the total CO32- peak area to the PO43- peak 
area, or total CO32- peak area to 1032 cm-1 peak area, however they either give similar 
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results or do not improve the calibration curve or the correlation coefficient (see 
Appendix, supplementary data 2, Figure B.9). 
The curve fitting results based on carbonate bands at 1456, 1423 and 1408 cm-1 were 
also tested for the calibration curve but they do not change or improve the correlation 
coefficient (R2 = 0.92) (see Appendix, supplementary data 2, Figure B.10). 
 
In parallel, an integration method was used and the ratio was calculated from the total 
area under each phosphate and carbonate peak. This also did not change or improve 
the calibration curve or the correlation coefficient (R2 = 0.95) (see Appendix, 
supplementary data 2, Figure B.11).  
 
3.4.2. Analysis of Raman spectra from cHap pellets 
 
A calibration curve was also derived using the ratio of the peak areas at 1070 and 960 
cm-1 for CO32- to the PO43- bands. These peak positions have previously been used in 
other studies [70], [74], [103], [104]. 
 




Figure 3.10 Linear regression of the plot of C:P ratio vs. % CO32- substitution in cHap pellet samples. 
Data were obtained from Raman spectra as the ratio of the peak area at 1070 cm-1 to 960 cm-1. Two 
replicates were performed in those experiments. Values are mean ± SD. Regression equation: y= 
1.239·10-2 x; R2 = 0.98.  
 
As illustrated in Figure 3.10, there is a linear regression of the plot of C:P ratio vs. 
amount of carbonate substitution with a high correlation coefficient (R2 = 0.98). 
The delicate part of this work using Raman spectra is that the carbonate and 
phosphate peaks are overlaid and this can lead to a bias in the calibration curve. 




This chapter which is devoted to the analysis of mineral standards confirms the 
possibility to analyse mineral compounds e.g. cHap, OCP, β-TCP and ACP using 
vibrational spectroscopy. Moreover, the analysis of minerals other than cHap, which 
is usually analysed in most studies, reveals that they exhibit similar features to cHap 
in both Raman and FTIR spectra. These results are crucial information for the rest of 
this study and can be translated to the analysis of biological samples and 
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microcalcifications. This study also highlights specific peaks of phosphate and 
carbonate (960 and 1070 cm-1, respectively) [103] found in cHap Raman spectra. For 
cHap FTIR spectra, specific peaks are observed at 1030 cm-1 for phosphate and 875, 
1408, 1423, 1456 cm-1 for type B carbonate ion substitution [88]. The cHap samples 
seem to contain type B CO32- substitution, which matches the information given by the 
manufacturer. The choice of using B type in this study is in line with the literature. In 
fact, for instance, dental enamel presents 90% type B CO32- substitution whilst only 
10% represents type A CO32- substitution [36] and the same results are found in bone 
mineral [100]. In breast microcalcifications, to date it has been demonstrated the 
presence of type B CO32- substitution only. However, the literature is sometimes 
contradictory: according to Ren et al., the carbonate peaks at 880, 1413 and 1450 cm-
1 are not characteristic of carbonated apatite. The presence of a sub-band at 880 cm-
1 could be the result of carbonate absorption at the surface of Hap crystal rather than 
in the lattice [88]. However, several studies are based on these peaks for assignment 
and validation of the method [100], [102]. 
The next step of this study was to determine the sub-bands contained in Raman and 
FTIR spectra in order to single out overlaid peaks e.g. at 1070 cm-1 for carbonate. 
The peak decomposition is a method commonly used in several studies of 
mineralisation [70] and mineral analysis [100] to decompose different regions in the 
spectra. Regarding the FTIR spectra, the samples present different profiles and can 
have additional or different components that can be assessed with second derivative 
analysis; however, even the second derivative spectra exhibit interferences and noise. 
Different elements can explain the noise and interferences. To avoid scattering 
artefacts in the FTIR spectra, a sample preparation using KBr pellets was necessary 
but not perfect, as pellets may differ in thickness, homogeneity and surface flatness. 
Moreover, the spectral limit at 700 cm-1 due to the MCT detector in the FTIR system 
can affect the spectral band shape in this region. Despite these limitations, the 
obtained calibration curves show a good linear regression between the different C:P 
ratios and the amount of carbonate substitution (R2 = 0.97 and 0.98 for FTIR and 
Raman data, respectively). The peak decomposition analysis seems to be more 
reproducible for Raman data than FTIR data: Raman spectra present the same 
number of components for carbonate and phosphate bands and similar peak positions. 
In Raman spectroscopy, no specific sample preparation is needed and the powders 
are directly analysed without any artefact in the spectra. 
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However, in parallel to this method, a PLS model will be applied to the spectra from 
biopsy samples to assess the amount of carbonate in each microcalcification. An 
integration method based on the total area under the phosphate and carbonate peaks 
would be easier and faster to calculate; however, for comparison with Raman data, it 
is not possible to apply it because the carbonate and phosphate peaks are overlaid. 
All in all, peak decomposition appears the most accurate method to analyse the 





Chapter 4 : Investigation of the chemical composition of 




Previous analyses of breast tissue sections using Raman and IR spectroscopies 
suggest that the grade of pathology is correlated to the chemical composition of 
microcalcifications, in particular the carbonate content in the Hap lattice or the protein 
level inside the microcalcification [59], [105]. 
 
 
Figure 4.1 Different breast lesions (Benign, in situ (low, intermediate and high grades) and 
invasive cancer grades 1, 2, 3) classified according to (a) the amount of CO32- and (b) the protein levels 
into breast microcalcifications assessed by FTIR spectroscopy. From R. Baker, 2010. 
 
Baker et al. have previously shown that in benign lesions, microcalcifications from 
breast tissues have a higher concentration of carbonate ion substitution than 
malignant lesions (see Figure 4.1a). Besides, protein level measured by calculating 
the amide-to-phosphate peak ratio increases going from benign to invasive lesions 
[59]. The same results have been found by Haka et al. by calculating the peak height 
of CO32- stretching at 1070 cm-1 and the FWHM of the PO43- peak at 960 cm-1 for each 
stage of breast cancer. They concluded that the CO32- peak is broader in benign 
lesions and it is not linearly correlated with the broadening of the PO43- peak, which 
means that different impurities were added in Hap crystal and these seem to be 




associated with proteins. They concluded that the protein level is higher in malignant 
lesions [105]. 
However, several questions remain to be addressed: why is the Hap crystal carbonate-
substituted specifically in benign lesions? Is the crystal disorder created by impurities 
only due to proteins and specifically in malignant lesions? Could the pH variation at 
different stages (as discussed in Chapter 3, section 3.1.2) play a role in Hap crystal 
formation and are its precursors involved? 
To answer these questions, a comparison between microcalcification features was 
made between frozen and paraffinised tissue sections for different stages of breast 
pathology. 
 
4.2. Chemical and spatial information on microcalcifications 
found in frozen breast tissues 
 
4.2.1. FTIR analysis 
 
FTIR spectroscopy-derived information were obtained for microcalcifications using the 
Agilent system with two different detectors, as described in Chapter 2, section 2.2.2. 
One approach was to record FTIR images and the second one was to record single 
FTIR spectra. 
As expected from the literature and shown in Figure 4.2, FTIR spectra of 
microcalcifications present structured phosphate and carbonate bands. FTIR images 
were recorded in the spectral range 3800-900 cm-1 which includes the CO32- peaks at 
around 1420 and 1450 cm-1 and the PO43- peak at around 1030 cm-1 (Figure 4.2a). 
Single point measurements were recorded in the spectral range 3800-800 cm-1 which 
also allows the detection of the CO32- peak at around 875 cm-1 (Figure 4.2b). There is 
a difference in the shape of the phosphate peak (1200-900 cm-1) between the mean 
spectrum from single point measurement (Figure 4.2b) and mean spectrum extracted 
from the FTIR image (Figure 4.2a). In fact, the mean spectrum from the single point 
measurement is an average of the entire microcalcification whereas the mean 
spectrum extracted from the FTIR image corresponds to a small area within the 
microcalcification. 





Figure 4.2 FTIR spectra of a microcalcification found in DCIS tissue obtained using (a) an FTIR 
image in the range 1800 to 900 cm-1 and (b) a single point measurement in the range 1200-830 cm-1. 
(c) Image of the H&E stained breast tissue taken with a transmission microscope, x10 objective. 
 
These data are rich in information but have also several disadvantages. The critical 
aspect of the single point measurements is that, for frozen tissues, the contribution 
from water vapour is very important at short wavelengths (protein or lipid peaks) and 
also in the carbonate region (at around 1420-1450 cm-1). The second aspect is that, 
in order to take a measurement, a large area is only selected manually with the Agilent 
system and it is impossible to use a specific spatial resolution. The advantage of this 
measurement over that conducted with the imaging system is that the carbonate peak 
at 875 cm-1 can be measured. In fact, with the FTIR FPA imaging system, it is 
impossible to record a spectrum below 900 cm-1 due to the limit imposed by the 
detector sensitivity; on the other hand, the imaging mode allows a selection of a 
specific spatial resolution (i.e. 5.5 m2 pixel size) on the contrary to the single point 
measurement and the carbonate peak in the 1400 cm-1 region is measurable. 
However, when tissue sections are embedded in paraffin, the carbonate peaks at 
1420-1450 cm-1 are often overlaid with the CH3 vibration of paraffin which makes this 
region non-exploitable. For these type of samples, correlative analysis using both 
single point measurements and FTIR images is useful. 




Another advantage of using the FTIR imaging system is that FTIR images give 
information about the spatial distribution of the microcalcifications within the tissue as 
shown in Figure 4.3. 
 
 
Figure 4.3 Visible and micro-transmission FTIR images of a DCIS breast cancer biopsy. (a) 
Histological section stained with H&E and imaged with a transmission microscope, x10 objective. (b) 
White light image acquired with an Agilent FTIR microscope. The images were recorded in the range 
1800 to 900 cm-1 and show the distribution of the phosphate peak intensity at 1020 cm-1 obtained using 
(c) 4x objective and (d) 15x objective. 
 
Figure 4.3 illustrates the good agreement in the apparent microcalcification observed 
in a histological section with H&E staining, a white light image and FTIR images based 
on the phosphate peak intensity at 1020 cm-1. All these micrographs exhibit the same 
morphological features. In the FTIR images, the microcalcification is represented in 
false colours, where red corresponds to high intensity at 1020 cm-1 and blue to low 
intensity. Thus, FTIR images allow the identification of microcalcifications in non-
stained (label-free) tissue sections and can be used as a guide for localised micro-
Raman analysis. These measurements were performed for each sample and different 
stages of breast cancer as shown in Figure 4.4. 





Figure 4.4 Histological sections with H&E staining and corresponding FTIR spectra for three 
breast lesions: (a) Benign, (b) DCIS low grade and (c) IDC grade 2. An average of 10 spectra (single 
point measurements) were taken from microcalcifications in the range 1200-830 cm-1. 
 
A comparison of spectra extracted from benign, DCIS low grade and IDC grade 2 
shows similar characteristics for phosphate and carbonate bands (see also Appendix, 
supplementary data 3, Figure C.1 showing spectra extracted from micro-FTIR 
images). Figure 4.4 shows that the phosphate peaks found for these species are 
numerous and are not simply related to a particular stage of pathology. In Figure 4.4a, 
the phosphate band (1200-900 cm-1) is defined by six sub-bands at 962, 1024, 1095, 
1115, 1140, and 1157 cm-1 corresponding to 1,3 PO43- bands and HPO42- containing 
apatite, whilst in Figure 4.4b, the phosphate peak shape is more defined with a 
shoulder at 1021 cm-1 (non-stoichiometric apatite) and three peaks at 962,1065, and 




1108 cm-1 (1 and 3 PO43- bands). The phosphate band in Figure 4.4c is broader than 
the other peaks (Figure 4.4a and b) and its shape looks similar to those found in ACP 
mineral standard (see Chapter 3). Several sub-bands are present such as 960, 1024, 
1095, 1115, 1140, and 1157 cm-1 for the 1, 3 PO43- bands and HPO42- containing 
apatite. All spectra exhibit the same carbonate peak at 872 cm-1 (± 2 cm-1) 
corresponding to 2 CO32-, which is less prominent than the phosphate peak (1200-
900 cm-1). 
 
In parallel, to get complementary information about the composition of 
microcalcifications, Raman analysis was performed for these breast tissue sections. 
  




4.2.2. Raman analysis 
 
An example of Raman data of a breast sample for a particular stage of DCIS is 
illustrated in Figure 4.5. 
 
Figure 4.5 Visible images and Raman map of a breast DCIS biopsy sample. (a) Histological 
section stained with H&E and imaged with a transmission microscope, x10 objective. The red box 
denotes a 391 x 410 m2 area where a Raman map was measured. (b) White light image acquired with 
a Renishaw Raman microscope. (c) Raman map showing the distribution of the phosphate peak 
intensity at 960 cm-1 obtained using a 50x objective. (d) Average of 10 Raman spectra extracted from 
the middle region of the microcalcification (c). 
 
Figure 4.5a displays a histological section with H&E staining, where the 
microcalcification appears in dark purple and the surrounding tissue in pink whereas 
the white light image taken from a Renishaw microscope (Figure 4.5b) shows a bright 
white microcalcification. Figure 4.5c illustrates the Raman map which refers to the 
phosphate peak intensity at 960 cm-1. The microcalcification is represented by the red-
to-green regions in the false colour image. The mean spectrum in Figure 4.5d 
(extracted from the red box in Figure 4.5c) exhibits several peaks of interest. In 
particular, three phosphate peaks at 583, 960 and 1032 cm-1 and one carbonate peak 
at 1071 cm-1 are noted, which correspond to the cHap crystal in microcalcifications. 




Other elements are present such as proteins and lipids: 1662 cm-1 Amide I (proteins), 
1440 cm-1 CH2 deformation (lipids and proteins), 1157 and 1526 cm-1 carotenoids 
(absent in normal tissue) [106]. Based on the spatial resolution of around 1 µm and 
the ability to extract pure calcification spectra from the middle of the microcalcification, 
i.e. with apparently no tissue included, it is possible to conclude that there is not only 
pure cHap crystal but also a mix of proteins and lipids. 
To gain a better understanding of the spatial distribution of these species, a PCA was 
applied to each Raman map. An example of PCA results showing the first nine PC 
scores and loadings are presented in Figure 4.6. In this example, the microcalcification 
was found in DCIS with a low grade (Figure 4.6a). As illustrated in Figure 4.6b, the 
PC1 score denotes the microcalcification (yellow) with a corresponding phosphate 
peak in the PC1 loading (Figure 4.6c). PC2 and PC3 scores denote the surrounding 
tissue (yellow) with a strong contribution of proteins and lipids in the corresponding PC 
loadings. The remaining PC loadings are less defined in terms of spatial distribution 
and have a lower signal-to-noise ratio which should not be used for the discrimination 
between microcalcifications and surrounding tissue. For clarity, the first three PC 
loadings and their peak assignment have been reported in Figure 4.7. The PC1 
loading (Figure 4.7a) shows a strong contribution of phosphate and carbonate peaks 
at 960 and 1071 cm-1 for cHap, as well as lipid and protein contributions at 1442 cm-1 
and carotenoids at 1157 and 1527 cm-1 [107], [108]. They appear to be located in the 
region of the microcalcification (yellow, Figure 4.6b). However, PC2 loading (Figure 
4.7b and c), associated to the surrounding tissue, show a strong contribution of 
collagen (proline and hydroxyproline: 875 and 854 cm-1), lipids (1447, 1300 and 1437 
cm-1), proteins (Amide I at 1667 cm-1) and carotenoids (1157 and 1527 cm-1) [107], 
[108].The PC3 loading exhibits a weak contribution of a phosphate mineral at 968 cm-
1 surrounding the Hap crystal (in orange, Figure 4.6b) and carotenoids (1157 and 1527 
cm-1) but also collagen at 873 and 938 cm-1 in the surrounding tissue area [106], [107]. 
The phosphate species found at 968 cm-1 could correspond to Mg-substituted 
whitlockite (or -TCMP), as suggested by Scimeca et al. [42]. These results are in line 
with the literature. According to several studies, carotenoids are expressed to prevent 
breast cancer and play a role in the immune system as antioxidants and anti-
proliferative agents [108], [109]. 
 





Figure 4.6 (a) Visible image of a breast DCIS (low grade) tissue section showing a 
microcalcification. The red box denotes a region where a Raman map was acquired. PCA was 
performed on the Raman map: (b) the first nine PC scores and (c) corresponding PC loadings. 





Figure 4.7 Loadings for (a) PC1, (b) PC2 and (c) PC3 showing the peak assignment. Pro: Proline, 
Hpro: Hydroxyproline, and Phe: Phenylalanine. 




For a comparison with the FTIR spectra (see above, Figure 4.4), Raman spectra were 
recorded from adjacent sections of benign, DCIS low grade and IDC grade 2 samples 
and illustrated in Figure 4.8. It shows similar characteristics between each other, in 
particular for phosphate and carbonate peaks at 960 and 1071 cm-1, respectively. 
Moreover, proteins (1256 and 1657 cm-1), lipids (1442 and 1300 cm-1) and carotenoids 
at 1125 and 1154 cm-1 are also well represented for each cancer type [107], [108]. 
 
 
Figure 4.8 Histological sections with H&E staining and comparison of Raman spectra of three 
breast frozen lesions: (a) Benign, (b) DCIS low grade and (c) IDC grade 2. An average of ten spectra 
were taken from microcalcifications and baseline correction was performed in the range 1800-500 cm-
1. Phe: phenylalanine. 




For frozen tissue sections, FTIR and Raman spectra are well defined by several 
components such as lipids, proteins, or cHap. However, access to fresh or frozen 
tissue is sometimes difficult and a series of samples which are formalin-fixed paraffin-
preserved (FFPP) provided by hospitals archives is often convenient. Unfortunately, 
paraffin has a strong contribution in the Raman spectra (1063, 1130, 1296 and 1436 
cm-1) [110] and FTIR spectra (1377, 1466, 2850, 2922, 2958 cm-1) [110] and interferes 
with specific features of microcalcifications, especially phosphate and carbonate 
bands. A possibility in the analysis of FFPP tissue sections is to remove paraffin from 
the samples. However, one question remains: does the de-paraffinisation process 
damage or affect the microcalcification integrity? Therefore, breast tissue sections 
embedded in paraffin for the FTIR analysis and de-paraffinised tissue sections for 
Raman analysis were analysed and the results shown in the following sections. 
 
4.3. Chemical and spatial information of microcalcifications 
found in breast tissues embedded in paraffin 
 
A batch of breast tissue sections was analysed using complementary methods. As 
described in Chapter 2, section 2.1.2, one breast section embedded in paraffin and 
mounted on BaF2 was used for the FTIR analysis and an adjacent breast section was 
mounted on stainless steel and de-paraffinised (as described in section 2.3.2.2) prior 
to the Raman analysis. 
 
4.3.1. FTIR analysis of paraffinised sections 
 
Breast tissue sections embedded in paraffin were analysed using the FTIR imaging 
system and single point measurements. An example is illustrated in Figure 4.9. 





Figure 4.9 Visible and micro-transmission FTIR images of a breast DCIS (grade 3) section. (a) 
White light image acquired with a Renishaw microscope, x15 objective. (b) FTIR image showing the 
distribution of the phosphate peak intensity at 1020 cm-1 obtained using a 15x objective. (c) Mean IR 
spectrum extracted from the FTIR image (red box in b) truncated to the range 1800-900 cm-1 and (d) 
mean IR spectrum from single point measurements (red box in a) truncated to 1200-830 cm-1. 
 
As discussed in relation to Figure 4.2, the shape of the phosphate peak is different 
between the mean spectrum from single point measurement (Figure 4.9d) and the 
mean spectrum extracted from the FTIR image (Figure 4.9c). The spectra are not from 
the same location within the microcalcification, as they measured at different times on 
different instruments. 
The FTIR spectra (Figure 4.9c-d) appear to exhibit the same characteristics as those 
from the frozen tissue. The phosphate peak is apparent between 1200 and 900 cm-1 
and carbonate peaks are observed at 872, 1420 and 1462 cm-1. Unfortunately, the 
peak of carbonate at 1462 cm-1 (red arrow in Figure 4.9c) is overlaid to the CH2 
scissoring of paraffin [110], which affects the peak decomposition analysis in this 
region (1400-1500 cm-1). However, the single point spectra between 900 and 800 cm-
1 are still exploitable. 
 




4.3.2. Raman analysis of de-paraffinised sections 
 
As discussed previously, the effect of de-paraffinisation on breast cancer 
microcalcification analysis was investigated using Raman microspectroscopy and an 
example is illustrated in Figure 4.10. 
 
Figure 4.10 Visible image and Raman map of a breast DCIS (grade 3) section. (a) White light image 
acquired with a Renishaw microscope. (b) Raman map showing the distribution of the phosphate peak 
intensity at 960 cm-1 obtained using a 50x objective. (c) Average of ten Raman spectra extracted from 
a region of the microcalcification (red box in b). 
  




The visible image (Figure 4.10a) shows a large microcalcification in black and the area 
of the micro-Raman acquisition (red box). The Raman map, which is based on the 
phosphate peak intensity at 960 cm-1 (Figure 4.10b), shows the microcalcification in 
false colour cyan. A mean Raman spectrum extracted from this map (Figure 4.10c) 
exhibits the same features as those of frozen tissue. Phosphate and carbonate peaks 
are observed at 960 and 1071 cm-1 for 1 PO43- and 1 CO32- bands, respectively, as 
well as proteins and lipids at 1671 and 1451 cm-1 [107], [108], which suggest that this 
microcalcification contains a mix of cHap, proteins and lipids. 
In a similar way as previously done for frozen tissue sections, a PCA was performed 
for each Raman map and results are shown for breast tissue with DCIS grade 3 in 
Figure 4.11a. The PC scores and loadings are presented in Figure 4.11b and c. As 
illustrated in Figure 4.11b, the PC1 score map denotes the microcalcification (yellow) 
with an important phosphate and carbonate contribution in PC1 loading (Figure 4.11c). 
The PC2 score map denotes the surrounding tissue (orange) with a strong contribution 
of proteins and lipids in PC2 loading. The other PC loadings are associated with the 
background. For clarity, the first two PC loadings and their peak assignments are 
reported in Figure 4.12. PC1 loading, associated to the microcalcification (Figure 
4.12a), shows a strong contribution of phosphate and carbonate peaks at 960 and 
1072 cm-1 for cHap, as well as a lipid contribution at 1295 cm-1 and proteins (1172 cm-
1 for tryptophan and Phenylalanine and 1257 cm-1 for Amide III). Less collagen (854, 
875, 936, and 1003 cm-1) and proteins (Amide I at 1678 cm-1 and CH2 deformation at 
1449 cm-1) are present in this area. However, PC2 loading (Figure 4.12b), associated 
to the surrounding tissue, shows a strong contribution of collagen (Proline and 
Hydroxyproline: 875, 936 and 854 cm-1), lipids (1295 and 1450 cm-1), proteins (1450, 
Amide III at 1235 and 1268 cm-1, Amide I at 1674 cm-1) and also Hap (960 cm-1) [107].  
 





Figure 4.11 (a) Visible image of breast DCIS (grade 3) tissue showing a microcalcification. The red 
box denotes a region where a micro-Raman map was acquired. PCA was performed: (b) the first nine 
PC scores and (c) corresponding PC loadings. 
 





Figure 4.12 (a) PC1 and (b) PC2 loadings showing the peak assignments for different contributions 
in Raman spectra. Pro: Proline, Hpro: Hydroxyproline, and Phe: Phenylalanine. 
  




Ó’Faoláin et al. have previously compared fresh, frozen and FFPP tissue sections 
using Raman microspectroscopy and concluded that the freezing or fixing process can 
have an impact on the protein and lipid intensity or their peak positions [110]. A shift 
in peak positions corresponding to CH2 deformation and Amide I is observed between 
frozen tissue (1442 and 1657 cm-1, Figure 4.8) and de-paraffinised tissue (1451 and 
1671 cm-1, Figure 4.10). However, the de-paraffinisation process does not appear to 
affect the chemical composition of Hap crystals, which are still well-represented by the 
phosphate and carbonate bands at the same positions as in frozen tissue. Further 
analysis will clarify this effect as well as the presence of other minerals in the 
microcalcifications. 
  




4.4. Peak analysis 
 
A mineral peak decomposition by curve fit analysis was performed for all datasets 
(FTIR and Raman spectra; frozen, paraffinised and de-parafinised tissues). 
 
 
Figure 4.13 Results from curve fit analysis applied to Raman spectra. Histological sections with 
H&E staining and comparison of Raman spectra of frozen tissues with three breast lesions: (a) Benign, 
(d) DCIS low grade and (g) IDC grade 2. Spectra were truncated to the phosphate band at 990-930 cm-
1 (b, e and h) and to the carbonate band at 1100-1020 cm-1 (c, f and i) and baseline corrected. For each 
fit, the regression is very good (R2 > 0.99). 
  




The results shown in Figure 4.13 for Raman spectra of frozen samples have been 
found to be very similar to those from de-paraffinised samples, in terms of peak 
positions and number of sub-bands (see Appendix, supplementary data 3, Figure C.2). 
The decomposed peaks illustrated in Figure 4.13 are associated with different 
vibrational modes of phosphate and carbonate ions (as described in Chapter 3) and 
are in line with several characteristics of the mineral standards analysed previously. 
For instance, the phosphate peaks at 945-947, 959 and 967 cm-1 correspond to the 1 
PO43- mode (Figure 4.13 b, e and h). In Figure 4.13 c, f and i, the peak positions at 
1031, 1041-1045, 1051, 1061, 1079 cm-1 are assigned to the 3 PO43- mode [36], [91], 
[103]. The carbonate peaks at 1070 and 1082 cm-1 are associated with the 1 CO32- 
mode [36], [91], [103]. The main carbonate peak at 1070 cm-1 is overlaid with the 
phosphate band and therefore it is challenging to determine the C:P ratio for each 
microcalcification. These results seem to indicate the presence of cHap in our 
microcalcifications, however the case is more complex. In fact, as described in 
Chapter 3, it is hard to discriminate cHap from ACP or β-TCP for example, due to a 
similar peak decomposition profile (similar sub-bands). For instance, Figure 4.13e and 
h show the same peaks at around 946, 959 and 967 cm-1 which may indicate the 
presence of β-TCP. However, the carbonate peak at 1070 cm-1 also suggests the 
presence of cHap. Here, microcalcifications from DCIS and IDC lesions could be a 
mixture of cHap and β-TCP. In contrast, the microcalcification within the benign lesion 
illustrated in Figure 4.13b and c is made of cHap only, with two peaks for phosphate 
band at 945 and 960 cm-1 and 1070 cm-1 for carbonate band. Nevertheless, it is 
impossible to assign a specific composition to microcalcifications for a specific stage 
of the pathology. Figure 4.13 illustrates the heterogeneity between microcalcifications. 
A curve fit analysis was also performed for other benign lesions (Appendix, 
supplementary data 3, Figure C.3) that exhibit an additional peak at 968 cm-1 without 
any carbonate bands, which is not the case in Figure 4.13b and c. This suggests that 
it could be possible to find β-TCP as a precursor of Hap, but not for all benign lesions. 
 
The same analysis was performed for the FTIR data and results are illustrated in 
Figure 4.14. 





Figure 4.14 Results from curve fit analysis of FTIR spectra from paraffinised breast tissue (benign 
lesion). (a) Second derivative spectrum between 1200 and 830 cm-1. Curve fit analysis was performed 
on spectra truncated to (b) the phosphate band at 1200-900 cm-1 and (c) the carbonate band at 890-
830 cm-1 and baseline corrected. For each case, the regression is very good (R2 > 0.99). 
 
The results shown in Figure 4.14 are representative of results for all the FTIR spectra 
for the single point measurement from frozen and paraffinised samples where the 
number of sub-bands is the same for the phosphate and carbonate bands (see 
Appendix, supplementary data 3, Figure C.4). However, a shift in a sub-band is noted 
from 959 cm-1 (paraffinised tissue) to 967 cm-1 (frozen tissue) for the 1 PO43- band, 
which is still unclear (Appendix, supplementary data 3, Figure C.4). Figure 4.14a 
shows the sub-peak positions that were used in the peak decomposition analysis 
(Figure 4.14b and c). The phosphate peak is well represented by eight components: 
1124 cm-1 corresponding to poorly crystalline Hap; 1100, 1077, 1030 and 1002 cm-1 
for the 3 PO43- mode; 1017 cm-1 for non-stoichiometric apatite; and 959 cm-1 for the 
1 PO43- mode [88], [89], [98]. For several DCIS and invasive breast lesions, additional 




peaks are found at 1150-1160 cm-1 which are due to the HPO42- ion in acidic 
environment [86], [99]. This tends to correlate with the pH changes observed during 
cancer progression, with a more acidic environment in advanced stages [84], [85]. In 
Figure 4.14c, even if a peak shift is noticed between second derivative spectrum and 
the curve fit analysis, the carbonate band is defined by four components: 881 cm-1 for 
the 3 CO32- mode; 872 cm-1 for the 2 CO32- mode; 860 cm-1 corresponding to the 2 
CO32- mode, unstable and non-apatitic; and 847 cm-1 for the 4 CO32- mode [98], [100], 
[111]. This denotes the same spectral characteristics as the mineral standards used 
for reference. FTIR spectroscopy is more challenging with materials that include 
crystals due to scattering. In addition, the limit of detection of carbonate peak in long 
wavenumbers and the weakness of the signal in this region are such that errors can 
arise during data processing. However, the comparison between microcalcifications 
and mineral standards can give some useful information. 
 
By comparing the sub-band positions from the curve fit analysis between standard 
minerals and breast tissue sections in the total dataset (frozen and de-paraffinised 
tissues), out of 49 microcalcifications analysed by Raman microspectroscopy, 20 
seem to be made of cHap only, 10 present the same patterns for cHap and β-TCP, 6 
are a combination of cHap and ACP, 6 may be made of β-TCP only, 2 present the 
same patterns for ACP, 4 microcalcifications show the same peak positions as cHap, 
ACP and β-TCP, and 1 seems to be a combination of cHap and OCP (see Appendix, 
supplementary data 3, Table C.1). 
Similarly, out of 48 microcalcifications analysed by FTIR spectroscopy (frozen and 
paraffinised tissues), 20 exhibit the same peak positions as a combination of cHap 
and ACP, 13 seem to be made of cHap only, 7 show the same patterns as cHap and 
β-TCP, 2 are made exclusively of OCP, 3 of a combination of cHap, β-TCP and ACP, 
2 microcalcifications is β-TCP only, and 1 microcalcification shows the same peak 
positions as cHap and OCP (see Appendix, supplementary data 3, Table C.1). 
Based only on the peak positions it is challenging to determine the chemical 
composition of breast microcalcifications and their predictions could be different from 
FTIR and Raman spectra when the microcalcifications are comparable (Appendix, 
supplementary data 3, Table C.1). For instance, regarding the FTIR spectra, ACP and 
cHap present the similar spectral characteristics which tend to challenge the 




discrimination between the two minerals (e.g. B9 to B11, and I1 for paraffinised/de-
paraffinised sections, Table A2.1). The only difference is that the phosphate peak at 
around 1030 cm-1 found for ACP is broader than that of cHap (Appendix, 
supplementary data, Table C.1). The same issue was encountered for OCP mineral 
predicted in D4 microcalcification (paraffinised/de-paraffinised sections, Table A2.1) 
for the FTIR spectra and only cHap seems to be present in Raman spectra. 
 
To have a precise idea of the microcalcification composition, all these data need to be 
investigated in detail for carbonate amount of each microcalcification or evaluation of 
mineral composition. 
 
4.5. Estimation of carbonate and other components content in 
microcalcifications 
 
4.5.1. Calculation of the C:P ratio 
 
Using the calibration curve illustrated in Chapter 3, the C:P ratio was calculated using 
the area under each peak obtained from the curve fit analysis. The C:P ratio was 
calculated by using carbonate peak at 1070 cm-1 and phosphate peak at 960 cm-1 for 
Raman spectra, whereas the carbonate peak at 875 cm-1 and the total phosphate peak 
area are used for the FTIR spectra. The results are listed in Table 4.1 and 4.2 for 
frozen and paraffinised/ de-paraffinised samples, respectively. For clarity, 
microcalcifications are numerated by their breast lesions, e.g. B for benign, D for DCIS, 
and I for invasive cancer. When the same microcalcification is analysed by IR and 
Raman spectroscopy (same area), a double red arrow is added in the table. 
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Table 4.1 Carbonate amount estimated in frozen breast tissue microcalcifications by curve fit analysis performed on Raman and FTIR spectra for three 
breast lesions: B: Benign, D: DCIS, and I: invasive cancer. Double red arrows are added to notify that the same microcalcifications were analysed by Raman 
and FTIR spectroscopy. If the double red arrows are missing, the microcalcifications analysed by Raman and IR spectroscopy are different. 
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Table 4.2 Carbonate amount estimated in paraffinised and de-paraffinised breast tissue microcalcifications by curve fit analysis performed on Raman and 
FTIR spectra for three breast lesions: B: Benign, D: DCIS, and I: invasive cancer. Double red arrows are added to notify that the same microcalcifications were 
analysed by Raman and FTIR spectroscopy. If the double red arrows are missing, the microcalcifications analysed by Raman and IR spectroscopy are different. 




The common range of carbonate ion substitution found in biological samples is around 
2-8 wt.% [112] with, for instance, around 6 wt.% for bone and 5 wt.% for dentine [38]. 
In the present case, whether frozen or paraffinised tissues, some samples show a very 
high carbonate content, e.g. 47 or 29 wt.%, (Table 4.2, microcalcifications B11 and 
B14) in microcalcifications analysed from FTIR spectra. The amount of carbonate 
calculated is often more than 10 wt.% for a several samples (Tables 4.1 and 4.2). 
Different combinations of ratios were calculated (875 cm-1 CO32- peak to total PO43- 
band area; total CO32- band to 1032 cm-1 PO43- peak area; or total CO32- band to total 
PO43- band area) and that does not change significantly the calculated content of 
carbonate in each microcalcification (data not shown). 
Regarding the Raman spectra, the amount of carbonate per microcalcification seems 
to be lower than that determined from IR and often less than 10 wt.% (except for I4 
with 20 wt.% in Table 4.1; B18, B19, D7 and D8 with 22, 25, and 40, and 29 wt.%, 
respectively, in Table 4.2), which is much more realistic physiologically. When a 
comparison could be made between FTIR and Raman spectra, the determination of 
the carbonate concentration is lower using Raman spectra (e.g. in Table 4.1, I20 
contains 19 wt.% carbonate for IR and only 6 wt.% for Raman). Different combinations 
of ratios were also tested for the Raman data but they did not improve the results any 
further. In the case of the highest concentrations of carbonate found for a few samples 
(e.g. in Table 4.1 for Raman spectra from de-paraffinised tissue sections), 
microcalcification D7 is around 40 wt.% for FTIR spectra from paraffinised tissue 
sections, B14 is around 47 wt.%. - their peak decomposition analysis shows common 
sub-bands with cHap, β-TCP and ACP which could affect the calculation and could 
explain their high concentrations due to the contribution of several minerals (e.g. ACP 
contains also carbonate ions and their proportion is unknown). The Hap crystal could 
also be substituted by other elements, such as Na and Al [41], or the carbonate ion 
substitution is not only type B but also a mix of A and B which can affect the C:P ratio. 
Moreover, for some microcalcifications, the signal was too weak or too noisy to enable 
the carbonate band to be decomposed and, as a consequence, another method needs 
to be applied in order to validate the previous results. 
  




4.5.2. Prediction of microcalcification composition 
 
A PLS model which is a supervised method was applied to predict the amount of 
carbonate in microcalcifications. Results are summarised in Table 4.3. The model was 
performed with Raman spectra for microcalcifications from frozen sections (Table 
4.3a) and de-paraffinised tissues (Table 4.3). As it is observed, the amount of 
carbonate for both sets of samples is in a reasonable range of 5.7 to 10.3 wt.% and 
5.8 to 9.6 wt.% for microcalcifications from frozen sections and de-paraffinised 
sections, respectively. These ranges are roughly similar in both cases. The PLS 
method seems to improve the prediction of carbonate amount. In fact, only one 
microcalcification has a high carbonate concentration (Table 4.3, B1 with 9.43 wt.% 
for frozen sections), which is better than calculations from curve fit analysis. As 
concluded previously, other compounds or other substitutions can interfere in the C:P 
ratio. All carbonate amounts in microcalcifications are roughly the same for frozen or 
de-paraffinised tissue sections. 
Unfortunately, due to the small number of microcalcifications, a correlation between 
the percentage of carbonate ion substitution and the degree of pathology is not 
possible here. The PLS method was also applied for the FTIR spectra but, as 
expected, it gave very high amount of carbonate substitution which does not seem to 
be realistic. The PLS model is based on specific features of cHap (phosphate and 
carbonate bands) and, in the case of the FTIR data, other factors could interfere in the 
prediction in terms of spectral features from protein and phosphate contribution of 
nucleic material (DNA). 
  




Table 4.3 Comparison of a PLS model and curve fit analysis for the carbonate amount prediction 
in frozen and de-paraffinised breast tissue microcalcifications. Analysis was performed on Raman 
spectra for three breast lesions: B: Benign, D: DCIS, and I: invasive cancer. Double red arrows are 
added to notify that the same microcalcifications were analysed for both methods. If the double red 
arrows are missing, the microcalcifications analysed by Raman and IR spectroscopy are different. 
 






The opportunity to have access to frozen tissue sections enabled a validation to be 
made for the composition of microcalcifications using vibrational spectroscopy. Even 
though the frozen and de-paraffinised sections were not the same for each sample, 
the de-paraffinisation process did not seem to affect the spectral signatures of the 
microcalcifications. In fact, for Raman spectra, the phosphate peak is always located 
at 960 cm-1 and the carbonate peak at 1070 cm-1, as it was for frozen sections and 
mineral standards (Chapter 3). This study has shown the heterogeneity in terms of 
proteins, lipids and carbonate content of microcalcifications between different samples 
from the same stage of pathology. In fact, some microcalcifications reveal the 
presence of carotenoids which have antioxidant and anti-proliferative effects [108], 
[109]. Due to the small number of samples, it is not possible to generalise the results 
according to a specific stage of pathology, and a larger number set for a specific type 
of sample (frozen sections or de-paraffinised sections) is necessary. Kunitake et al. 
have suggested that the collagen network is embedded or in contact with the surface 
of the microcalcification and plays a role to protect the surrounding tissue from the 
inflammatory process enhanced by microcalcification itself [113]. Second Harmonic 
Generation (SHG) or polarised FTIR spectroscopy could be effectively applied to 
localise and bring new information about the organisation of collagen fibres around 
microcalcifications in breast sections for different stages of disease and different 
shapes of microcalcifications. A correlation could be done between the Raman maps, 
FTIR and SHG images. In our samples, it was found that a large majority of 
microcalcifications contain carbonate ion substitutions in the Hap lattice. As discussed 
previously, the carbonate content increases in benign lesions [59] which is expected 
in our study but, considering the difficulties of evaluating the carbonate content, e.g. 
by curve fitting analysis, integration method or PLS model, and also the small number 
of samples, it is not possible to make definitive conclusions. Nevertheless, the PLS 
method applied to Raman spectra provides a realistic amount of carbonate ion 
substitution in microcalcifications which is in the same range for both types of sections 
(frozen or de-paraffinised) and is promising for further analysis. 
The other challenging point is the use of FTIR spectroscopy and imaging with 
scattering due to the Hap crystal or cHap pellets which can add a bias in the calculation 




of carbonate content. However, this study supports the hypothesis of intermediate 
mineral phases in microcalcifications. In addition, other elements substituted such as 
Mg, Na or Al could also affect the C:P ratio. These elements have been highlighted in 
breast microcalcifications using X-ray diffraction [41], [113]. In fact, it has been 
demonstrated that magnesium-substituted whitlockite (or -TMCP) is increased in 
DCIS and invasive breast lesions based on changes observed for the Hap crystal 
[114]. X-ray techniques could offer a good complementary approach for exploring the 
elemental composition of microcalcifications. A study using micro-CT scan and X-ray 
fluorescence has shown the feasibility to localise quickly the microcalcifications in 
block breast sections and histological sections [115]. The combination of all these 
techniques (vibrational spectroscopy, X-ray diffraction etc.) can contribute to improve 
the knowledge about microcalcifications. Nevertheless, due to the heterogeneity of 
microcalcifications in terms of size and morphology [32], [35], [113] (as discussed in 
Chapter 1) or the small number of different compounds, their analyses remain 
challenging. Another approach seems to be necessary such as the study of in vitro 
microcalcifications. By using a cellular model of mineralisation, it may be possible to 





Chapter 5 : Assessment of breast cancer cell 




Many studies have investigated spectroscopy to probe the physiological and 
pathological mineralisation using different cell lines [104], [116], [117], but not a single 
one has yet focused on in vitro mechanisms of breast microcalcifications. The first in 
vitro model of mammary cell mineralisation was developed in 2012 by a team at the 
RSCI led by Dr Morgan using different breast cancer cell lines in order to study the 
molecular mechanisms involved in breast microcalcifications [118], [119]. To simplify 
the process, osteogenic agents are added to induce cell mineralisation, where -
glycerophosphate (G) is a source of inorganic phosphate (Pi) for cells, ascorbic acid 
(AA) promotes collagen production and Dexamethasone (Dex) induces osteoblastic 
differentiation [120] which promote Hap formation and propagation in the ECM. Their 
first experiments used a murine mammary 4T1 cell line [118]. As illustrated in Figure 
5.1a-c, mineralisation was followed at day 4 to 28 after induction. The mineralisation 
was assessed using Alizarin red (AR) staining (Figure 5.1a), which is commonly used 
to visualise rich calcium deposits [121], and validated by a calcium assay through an 
elevated calcium level in these calcifications (Figure 5.1b). The mineralisation was 
also studied by Raman micro-spectroscopy after 28 days of mineralisation using the 
phosphate peak at 960 cm-1 specific to Hap (Figure 5.1c). The formation of calcium 
deposits was induced by an osteogenic cocktail (OC) added in a regular medium, 
which contains a combination of G and AA. In addition, they found that the 
microcalcification formation was dependent of the alkaline phosphatase (ALP) activity 
to produce inorganic phosphate (Pi), essential for Hap crystal formation [118]. Their 
results were promising and the protocol of mineralisation was applied to a human 
mammary MDA-MB-231 cell line [119]. In a manner similar to their previous study, cell 
mineralisation was assessed using AR staining and calcium assay after 28 days. In 
contrast to the murine cell line, MDA-MB-231 cells required an OC supplemented with 
Dexamethasone (Dex) to induce calcium deposits (Figure 5.1d and e). These 
experiments shown the ability of mineralisation of a human breast cancer cell line. This 
model is an opportunity to investigate molecular mechanisms involved in the 




mineralisation process to understand the occurrence of microcalcifications in 
mammary gland.  
 
 
Figure 5.1 Assessment of mineralisation of MDA-MB-231 cell line using an osteogenic cocktail 
(OC) made of ascorbic acid, β-glycerophosphate and Dexamethasone (Dex). The mineralisation was 
followed at day 7 to 28 for (a) 4T1 cells and (d) MDA-MB-231 cells using Alizarin red staining at x100 
magnification. (b, e) The calcium level was determined using the o-cresolphthalein calcium assay and 
normalised to protein. (c) Raman spectrum of calcium deposits found in 4T1 cells after 28 days of 
mineralisation. Adapted from [119], [120]. 
 




The collaboration with Dr Morgan was conducted as part of the EU Marie Curie Mid-
TECH project and the aim of our study was to explore the calcium deposits in this 
MDA-MB-231 mammary cell model to evaluate their composition over time by using 
vibrational spectroscopy. Thus, this model allowed us to follow the maturation process 
and then to correlate specific spectral features of microcalcifications to our breast 
biopsies at different stages of the disease.  
 
5.2. Time-course of the mineralisation 
 
In our study, two different pathways were evaluated, i.e. cells grown by adding 
inorganic phosphate (Pi) and Dex or by using an OC (G + AA+ Dex) in their culture 
media as described in Chapter 2, section 2.3.6. 
 
 
Figure 5.2 Representative images of MDA-MB-231 cells growing at different time point of 
mineralisation (Day 3, 7, 11 and 14). Cells grown on BaF2 substrate in control medium (regular medium), 
OC (osteogenic cocktail: G + Ascorbic acid + Dexamethasone) and Pi + Dexamethasone medium. 
(n=3). X100 magnification, scale bar represents 50 m. Figure provided by S. O’Grady from the RSCI. 
 




Figure 5.2 illustrates cells growing on BaF2 substrate for each condition up to 14 days. 
This figure shows that cells treated with Pi for 11 and 14 days are more aggregated 
than cells at day 3 or the control group. This was not found to be the case when cells 
are grown on plastic within 6-well plates. Moreover, it is not possible to grow cells 
beyond 14 days when they are treated with Pi without damaging the BaF2 substrate. 
Both these factors are not a good combination for cell survival. 
However, besides these points, for our study it was possible to follow and assess the 
mineralisation at different time points using Raman micro-spectroscopy. 
 
5.2.1. Spectral characteristics 
 
As illustrated in Figure 5.3a, cells treated with Pi present the onset of mineralisation 
only three days after their treatment (blue spectrum) compared to the control and cells 
treated with OC+Dex (or G) (red and green spectra). In fact, the Raman spectrum of 
cells treated with Pi (blue spectrum) exhibits a distinct peak at 960 cm-1 corresponding 
to the 1 PO43- mode of Hap. For all conditions, we found spectral features related to 
proteins (Amide I and III) and lipids at 1656, 1338, 1300, 1257 and 1447 cm-1, but also 
collagen with hydroxyproline and proline signals at around 853, 875 and 935 cm-1. 
Regarding the cells treated with G, the mineralisation process begins at day 11 
(Figure 5.3b, green spectrum) and the spectrum shows a peak shifted to 956 cm-1 
compared to the spectrum from cells treated with Pi at 959 cm-1 (blue spectrum). A 
phosphate peak at 587 cm-1 corresponding to the 4 PO43- mode [70] is apparent in 
the spectrum of cells treated with Pi at day 3 (blue spectrum, Figure 5.3a). At day 11, 
this peak is present in spectra of cells treated with Pi and G at 587 and 584 cm-1, 
respectively (blue and green spectra, Figure 5.3b). When cells are treated with G, a 
shift is observed for both 1 PO43- and 4 PO43- bands. This suggests the presence of 
another mineral phase in the in vitro microcalcifications. It is also noted that there are 
several peaks, as previously, corresponding to proteins and lipids but weaker when 
cells are treated with G than control cells. For further information, spectra from cells 
at day 7 and 14 are illustrated in Appendix, supplementary data 4, Figure D.1. No 
phosphate peak at day 7 for cells with G is noted. At day 14, the peaks for lipids and 
proteins are weaker for cells treated with Pi and G than those from the control group. 





Figure 5.3 Raman spectra acquired from breast cancer cells after 3 days (a) and 11 days (b) of 
mineralisation. Pi: inorganic phosphate, OC: osteogenic cocktail, Dex: Dexamethasone, Phe: 
Phenylalanine, Cys: Cysteine, Tyr: Tyrosine. Cells were treated with Pi+Dex and OC+Dex (G). Non-
treated cells are considered as control. Each spectrum is an average of 40 spectra for each condition. 
 
5.2.2. Principal Component Analysis 
 
To understand the chemical changes underlying the mineralisation process, a PCA 
was performed on the spectra extracted from breast cancer cells for each condition 
(Figure 5.4): control (red dots), cells treated with G (green dots) and Pi (blue dots). 




This allows a follow-up of the mineralisation process at day 3, 7, 11 and 14. Figure 5.4 
illustrates PCA score plots and corresponding PC loadings. 
 
 
Figure 5.4 Principal Component Analysis (PCA) applied to 40 Raman spectra collected from 
breast cancer cells after 3 days (a), 7 days (b), 11 days (c) and 14 days (d) of mineralisation and for 
each condition (control in red, cells treated with βG (OC+Dex) in green and Pi+Dex in blue). PC1 and 
PC2 loadings are shown in blue and red, respectively. 
 
At day 3 and 7 (Figure 5.4a and b), the cells treated with βG and control cells appear 
to belong to the same cluster (blue ellipse). PC 1 and 2 represent 58.68% and 22.41% 




at day 3 and 60.63% and 28.18% at day 7 of the entire variance in the dataset. As 
expected, cells treated with Pi (blue dots) induce a faster mineralisation (day 3, Figure 
5.4a) compared to the cells treated with βG which occurs only at day 11 (Figure 5.4c). 
Moreover, calcium deposits from Pi culture medium exhibit more phosphate and less 
proteins than control group (Figure 5.4b and c, PC1 and 2 loadings). At day 11 and 14 
(Figure 5.4c and d), clusters are inverted and control cells are in a different group than 
cells treated with Pi and βG (blue ellipse). PC1 and 2 represent 65.25% and 20.8% at 
day 11 and 81.38% and 8.11% at day 14 of the entire variance in the dataset. As 
discussed above, cells treated with βG have started their mineralisation and present 
a phosphate peak at 957 cm-1. In parallel, there is an important level of phosphate and 
less of proteins than the control group in their calcium deposits. However, at day 11, 
calcium deposits from both the culture media present an unexpected increase of 
protein level (Figure 5.4c and d, PC1 and 2 loadings). 
In order to have a follow-up of the mineralisation process, PCA was also performed 
for each day and condition together. PCA score plots as well as PC 1 and 2 loadings 
and PC1 and 3 loadings are illustrated in Figure 5.5. 
For PCA with PC scores 1 and 2, which represent 57.48% and 27.13% of the entire 
variance in the dataset (Figure 5.5a), two clusters are distinct: 
- Control cells (all days) and cells treated with βG at day 3 and 7 (blue crescent-
shaped). 
- Cells treated with Pi (all days) and cells treated with βG at day 11 and 14 (blue 
ellipse). 
PC 1 and 2 loadings show that calcium deposits from Pi and βG culture medium for 
day 11 and 14 have a high level of phosphate and less proteins than the control group. 
For PCA with PC scores 1 and 3, which represent 57.48% and 6.30% of the entire 
variance in the dataset (Figure 5.5b), three clusters are distinct: 
- Control cells (all days) and cells treated with βG for day 3 and 7 (blue ellipse 1). 
- Cells treated with Pi (all days except for day 14) and cells treated with βG for day 11 
(blue ellipse 2). 
- All cells treated with osteogenic agents at day 14 (blue ellipse 3). 
PC 1 and 3 loadings show similar results. There is an increase in phosphate content 
(peak at 958 cm-1) and less lipids and proteins (1448 and 1656 cm-1) as the 
mineralisation evolves compared to control and both Pi and βG culture media.




Figure 5.5 PCA plots from 40 Raman spectra acquired from breast cancer cells 3 days (blue), 7 days (red), 11 days (green) and 14 days (orange) of 
mineralisation and for each condition (control in dot, cells treated with βG (OC+Dex) in square and Pi in triangle). (a) PC 1 and 2 score plots and their loadings 
(blue and red) and (b) PC 1 and 3 score plots and their loadings (blue and green).




5.2.3. Spatial distribution of calcium deposits 
 
PCA was applied to the Raman maps in order to localise different sites of 
mineralisation. Results at days 11 and 14 for cells treated with Pi and βG are illustrated 
in Figures 5.6 to 5.13. 
 
Figure 5.6 PCA performed on a Raman map collected from breast cancer cells treated with Pi 
after 11 days of mineralisation. (a) White light image of breast cancer cells, (b) the first nine PC scores, 
and (c) corresponding PC loadings. 





Figure 5.7 Loadings for (a) PC1, (b) PC2 and (c) PC3 showing peak positions for different 
contributions in Raman spectra for breast cancer cells treated with Pi after 11 days of mineralisation. 




Figure 5.6 illustrates the PCA scores and loadings for cells with Pi in the medium after 
11 days of mineralisation and, for clarity, Figure 5.7 shows PC1, 2 and 3 loadings and 
their peak assignments. PC1 loading shows that cells contain a combination of 
proteins and lipids (1654, 1445, 1300, 1621 cm-1 for Amide I, CH2 deformation and 
Amide III) [106], [108], [122] and carotenoids at 1157 cm-1. Their co-localisation is 
represented by yellow colour in the PC1 score (Figure 5.6b). In orange, DNA signal is 
well-represented by peaks at 665 and 798 cm-1 [106], [107]. PC2 exhibits a 
combination of phosphate, lipid and protein peaks and they are represented by yellow 
spots (red arrows, Figure 5.6b), whereas PC3 loading is mainly due to calcium 
deposits (peak at 959 cm-1) represented by a yellow spot (red arrow, Figure 5.6b). 
In the same way, for cells growing in the Pi medium after 14 days of mineralisation 
(Figure 5.8 and 5.9), the main components are defined by PC 1, 2 and 3. The PC1 
score represents the nucleus of cells (yellow and orange, Figure 5.8b) whilst the PC2 
score is defined by the calcium deposits with several small yellow spots (red arrows, 
Figure 5.8b). The PC3 represents the cytoplasm of cells (Figure 5.8b, in yellow and 
orange). As previously, PC 1, 2 and 3 loadings and their peak assignments are shown 
individually for clarity in Figure 5.9. In the PC1 loading, the nucleus is rich is DNA 
(Figure 5.8b, PC1 score, in orange) with peaks at 677 and 794 cm-1 [106], [107]. This 
area is also rich in lipids and proteins (1654, 1445, 1333 and 1303 cm-1 for Amide I, 
CH2 deformation and Amide III, respectively) [106], [108], [122] and identified by yellow 
colour (Figure 5.8a, PC1 score). The PC2 loading shows a high phosphate peak for 
Hap at 959 cm-1 corresponding to calcium deposits in small spots (Figure 5.8b, red 
arrows) without proteins or lipids (Figure 5.9b). 
 





Figure 5.8 PCA performed on a Raman map collected from breast cancer cells treated with Pi 
after 14 days of mineralisation. (a) White light image of breast cancer cells, (b) the first nine PC scores, 
and (c) corresponding PC loadings. 
 





Figure 5.9 Loadings for (a) PC1 (b) PC2 and (c) PC3 showing peak positions for different 
contributions in Raman spectra for breast cancer cells treated with Pi after 14 days of mineralisation. 
 




The same analysis was performed on Raman maps from cells treated with βG, and 
similar results are found after 11 and 14 days after of mineralisation. PC scores and 
their loadings at day 11 and 14 are shown in Figure 5.10 to 5.13. 
At days 11 and 14, for PC1 loading, DNA is defined by peaks at 655/671 cm-1 and 
796/798 cm-1 (Figures 5.11a and 5.13a), which is represented in orange by PC1 score 
(Figures 5.10b and 5.12b).  
At day 11 and 14, calcium deposits and cytoplasm are well-defined separately. In 
Figure 5.11b, at day 11 PC2 loading is described by a combination of proteins and 
lipids in the cytoplasm of cells at 1443 and 1658 cm-1 (yellow and orange in PC2 score 
Figure 5.10b), whereas at day 14 the cytoplasm is represented by the PC3 loading 
(PC3 score, in yellow, Figure 5.12b). 
The calcium deposits are represented in yellow spots by PC3 score for day 11 and 
PC2 score for day 14 (red arrows, Figures 5.10b and 5.12b). These microcalcifications 
exhibit a strong phosphate peak at 958 and 957 cm-1 without any proteins or lipids 
(PC2 and 3 loadings, Figure 5.11b and Figure 5.13c). 
However, by comparing phosphate peak positions, a shift is noticed between both 
conditions (Pi and βG treatment). In fact, when cells are treated with Pi, the phosphate 
peak is around 959-961 cm-1 while when cells are treated with βG it is around 957-958 
cm-1 at day 11 and 14 of mineralisation, which is in line with the previous results and 
suggests the possibility of the presence of another mineral [116]. 
 





Figure 5.10 PCA performed on a Raman map collected from breast cancer cells treated with βG 
after 11 days of mineralisation. (a) White light image of breast cancer cells, (b) the first nine PC scores, 
and (c) corresponding PC loadings. 
 





Figure 5.11 Loadings for (a) PC1, (b) PC2 and (c) PC3 showing peak positions for different 
contributions in Raman spectra for breast cancer cells treated with βG after 11 days of mineralisation. 
 





Figure 5.12 PCA performed on a Raman map collected from breast cancer cells treated with βG 
after 14 days of mineralisation. (a) White light image of breast cancer cells, (b) the first nine PC scores, 
and (c) corresponding PC loadings. 
 
 





Figure 5.13 Loadings for (a) PC1, (b) PC2 and (c) PC3 showing peak positions for different 
contributions in Raman spectra for breast cancer cells treated with βG after 14 days of mineralisation. 
 
As discussed in Figures 5.4 and 5.7, cells treated with Pi at day 11 exhibit calcium 
deposits with a combination of proteins and lipids, which is not the case at day 14, 
where only a phosphate peak is observed. The calcium deposits from cells growing 
with βG at day 11 and 14 do not have proteins or lipids and the phosphate peaks are 




shifted compared to cells treated with Pi. This suggests different mechanisms of 
mineralisation. Moreover, these microcalcifications seem to be outside the cells for 
cells treated with Pi and βG, however further investigations are needed using higher 
spatial resolution. 
In this context, few samples containing cells treated with Pi and βG after day 11 of 
mineralisation were sent to Synchrotron Australia and Synchrotron Soleil in France for 
tests. Tobin et al. have used macro-attenuated total reflection Fourier Transform 
infrared (ATR-FTIR) spectroscopy. This technique is based on the absorption of an 
evanescent field generated by the reflection of IR light at the interface between an 
ATR crystal and the biological sample [123], [124]. In our case, a spatial resolution of 
0.5 m and 2 m was applied which is higher than that of our system in transmission 
mode. An example is illustrated in Appendix, supplementary data 4, Figure D.2 
showing an external calcium deposits with a strong phosphate region in the cells (red 
areas, white arrows) for both conditions, Pi and βG treatments, which is more evident 
using FTIR spectroscopic imaging (Appendix, supplementary data 4, Figure D.3) with 
a 3 m spatial resolution. In addition, Kansiz et al. have applied optical photothermal 
infrared (O-PTIR) spectroscopy on few samples. In this technique, a mid-IR laser 
induces photothermal effect into the biological sample surface, which is detected by a 
visible laser thus providing enhanced spatial resolution [125]. An example is shown in 
Appendix, supplementary data 4, Figure D.4 and the spatial resolution used in this test 
was 0.4 m, which is the same as that of ATR-FTIR spectroscopic imaging but without 
the disadvantage of damaging the sample by contact with the crystal. The results show 
several small spots (red arrows) with a high phosphate intensity, which correspond to 
calcium deposits by cells. These results seem promising and further investigations are 
necessary with several replicates for reproducibility. 
  




5.3. Analysis of mineralisation 
 
5.3.1. Peak analysis 
 
A peak decomposition by curve fit analysis was performed for all Raman and IR 
spectra, including each day and condition. Figure 5.14 illustrates the results of a peak 
decomposition applied to Raman spectra for each 1 PO43- band between 985 and 915 
cm-1 for cells treated with Pi (day 3 to 14) and cells with βG (day 11 and 14).  
For cells treated with Pi, the phosphate band exhibits four components at 967, 958, 
950 and 943.5 cm-1 which corresponds to 1 PO43- and 3 PO43- bands. For information, 
regarding the other replicates, the phosphate peak at 959 cm-1 is shifted to 959.7 cm-
1. 
The presence of all these peaks in the phosphate band is in line with previous results 
and could be related to a combination of cHap and OCP minerals (OCP is defined by 
three peaks at 968, 960 and 945 cm-1 as described in Chapter 3). The peak at 936 cm-
1 found at day 3 could be due to proline, which corresponds to the -helix of collagen 
[107], [126] and this is in line with the observation done in Figure 5.3a. 
For the cells treated with βG, the components are 966, 956, 950 and 942 cm-1 which 
could be a combination of -TCP and cHap or ACP (-TCP is defined by 966 and 957 
cm-1 and ACP by 958 and 945 cm-1, see Chapter 3). In fact, the presence of the shifted 
phosphate peak at 956 cm-1 supports this hypothesis. 
 
In parallel, a curve fit analysis was also performed on the 1 CO32- band between 1095 
and 1020 cm-1, when it was possible due to weak signals, and illustrated in Appendix, 
supplementary data 4, Figure D.5. A small peak at 1070 cm-1, resulting from the curve 
fit analysis suggests the presence of small amount of carbonate ion substitution in the 
samples. The same analysis has been done for each replicate and are reproducible 
(data not shown). These results enable to calculate the C:P ratio or the crystallinity of 
Hap, even give complementary information about the quantity of different precursors 
in the samples. 





Figure 5.14 Results from curve fit analysis of Raman spectra from cells treated with Pi + Dex at 3, 7, 11 and 14 days of mineralisation and OC+Dex (βG) at 
11 and 14 days of mineralisation. Spectra were truncated to the phosphate band at 985-915 cm-1 and baseline-corrected. For each case, R2 > 0.99. 
 




5.3.2. Carbonate-to-phosphate ratio 
 
The C:P ratio was calculated using the results from curve fit analysis and based on 
the ratio between carbonate peak at 1070 cm-1 and phosphate peak at 960 cm-1 using 
the areas under each peak. By comparing the ratio with that found in the calibration 
standards as outlined in Chapter 3, we determined the amount of carbonate ion 
substitution from Raman spectra of cells treated with Pi or G at day 3, 7, 11 and 14 
of mineralisation. The ratio and the amount of carbonate estimated for each sample 
are listed in Appendix, supplementary data 4, Table D.1. 
 
 
Figure 5.15 C:P ratio based on the area under the carbonate peak at 1070 cm-1 and phosphate 
peak at 960 cm-1 for the different treatments (OC+Dex and Pi+Dex) and different days of mineralisation. 
Data are presented as a mean ± SD. Two-way ANOVA test was performed, P=0.0005***. 
 
Figure 5.15 shows an increase of carbonate content in Hap lattice for cells treated with 
G during the mineralisation process. In fact, the carbonate content of cells after 11 
days was found to be around 3.5 wt.% and rose to 4.7 wt.% after 14 days. While the 
mineralisation of cells treated with Pi starts after 3 days of initiation, the incorporation 
of carbonate into the Hap crystal (at least to greater levels than the detection limit) 
appears after 7 days of mineralisation varying between 1.8 and 2.7 wt.% and increases 
up between 2 to 9.5 wt.% at day 11. It seems to decrease after 14 days with 2.3 to 5 
wt.% (the carbonate content for each replicate is listed in Appendix, supplementary 4, 




Table D.1). The variations of carbonate content in microcalcifications observed 
between the three replicates may be due to the curve fit analysis, the spectral quality 
or the differences in cHap crystal growth. By getting information of the crystal size for 
both conditions, it should allow to highlight different processes of Hap crystal growth. 
 
5.3.3. Hap crystallinity 
 
Several studies suggest that the crystallinity or the size of Hap crystal can be related 
to the inverse of the full width at half maximum (FWHM) of the peak at 960 cm-1 for 1 
PO43- mode [70], [126]. Based on the results obtained from this curve fit analysis, the 
inverse of the FWHM of phosphate peak was calculated and the results are 
summarised in Figure 5.16. 
 
 
Figure 5.16 Hap crystallinity based on the inverse of the FWHM of peak at 960 cm-1 after 3, 7 11 
and 14 days of mineralisation and for both treatments Pi and G. Data are presented as a mean ± SD. 
Two-way ANOVA test was performed, P< 0.0001**** and P< 0.0001**. 
 
The maturation of Hap crystal in Pi condition is faster than G condition, which is not 
surprising considering the mechanism of phosphate uptake by cells. As discussed in 
Chapter 1, G must be hydrolysed by the ALP enzyme to release a free phosphate at 
the surface of the cell. Then, phosphate is absorbed by the cell via transporter 




channels. In case of a medium supplemented with Pi, this one is directly absorbed by 
the cell to induce microcalcifications. In this context, Figure 5.16 shows a stable size 
of Hap for days 3 to 14 of mineralisation when cells are treated with Pi. Cells treated 
with G developed a smaller crystal than Pi condition. 
Legeros at al. have suggested that the incorporation of ion substitution such as Mg2+ 
or CO32- ions in the Hap lattice could reduce the stability of the crystal and induce a 
higher solubility [80]. Figure 5.15 shows that calcium deposits released from cells 
treated with G have more CO32- incorporated in their Hap lattice, which is in line with 
their lower crystal size (Figure 5.16) than that from cells treated with Pi. 
 
5.3.4. Other mineral phases 
 
Microcalcifications are mainly described and classified by their mineral content such 
as calcium oxalate and Hap. However, the presence of mineral precursors has been 
investigated in several studies during bone formation, osteoblast differentiation or 
mineralisation of jaw periosteal cells [69], [70], [127]. The following results are focusing 
on the intermediate species present in our samples, based on the peak decomposition 
analysis in Figure 5.14. The results are summarised in Figure 5.17. 
 





Figure 5.17 Involvement of different calcium phosphate phases in breast cancer cell mineralisation. 
(a) cHap, (b) -TCP, and (c) OCP. Data are presented as a mean ± SD. Two-way ANOVA test was 
performed, P = 0.0215*, P = 0.0004*** and P < 0.0001****. 
 
In G culture medium, the calcium deposits appear to be made of cHap, OCP and -
TCP at day 11 and 14. For cells treated with Pi, cHap and -TCP, the deposits are 
present in the microcalcifications at day 3 to 14. Moreover, no OCP deposits are found 
in these microcalcifications, which is the opposite of those found in G culture medium. 
Hap and ACP minerals are not easy to discriminate due to the same spectral features. 
Moreover, other approaches such as X-ray diffraction should allow us to determine the 
elemental composition and whether the -TCP is magnesium-substituted as it is found 
in other calcifications [41], [42]. These results reveal that calcium deposits are different 
in both culture media. Calcium deposits are more stable in terms of crystallinity, 
carbonate incorporation, and occur faster for a medium supplemented with Pi than G 
culture medium. 
  




Further analyses are necessary to understand the full process of microcalcification 
maturation and to investigate if a particular phosphate species could be a predictive 
factor for potential malignancy in breast. In this context, it is possible to correlate these 
results with those obtained from breast tissue sections, and to compare them in terms 
of spectral characteristics and peak decomposition. 
 
5.4. Exploring the relationship between breast cancer cell 
mineralisation and different stages of the disease 
 
A comparison was performed between Raman spectra recorded for breast cancer 
cells and breast tissue sections. The results are illustrated in Figure 5.18. 
Several spectral features are similar between breast tissues and breast cancer cells 
in terms of 4 PO43-, 1 PO43- bands and 1 CO32- bands for phosphate and carbonate 
corresponding to cHap of microcalcifications but also lipids and proteins with CH2 
deformation and Amide I, respectively. In contrast to breast cancer cells, carotenoids 
are found in breast tissue for benign and DCIS lesions. A double peak is noted for CH2 
deformation from DCIS and invasive lesions. The first peak at 1442/1444 cm-1 
corresponds to a combination of proteins, fatty acids and cholesterol and the second 
peak at 1456/1459 cm-1 (Figure 5.18, red arrows) corresponds to the deoxyribose in 
DNA [106], [122]. 





Figure 5.18 Average Raman spectra recorded from microcalcifications in benign, DCSI and 
invasive breast sections and compared with in vitro microcalcifications from breast cancer cells treated 
with (a) OC + Dex at day 11 and 14 of mineralisation and (b) Pi + Dex at day 7, 11 and 14 of 
mineralisation. Phe: phenylalanine, OC: osteogenic cocktail and Dex: dexamethasone. 
 
Similar spectral characteristics are found in breast cancer cells and breast tissue 
spectra in terms of phosphate peak positions but also lipids and proteins. Same results 
are found when a comparison is made between curve fit analysis of phosphate and 
carbonate bands from breast cancer cells and breast tissues (see Figure 4.14, Chapter 
4 and Figure 5.14). The positions and number of sub-bands for phosphate and 
carbonate bands are quite similar. The results suggest that different phosphate 
species and not only Hap are involved in the mineralisation process, and the in vitro 
model could be used for their identification. 






Raman micro-spectroscopy reveals a phosphate peak at 956/960 cm-1 suggesting the 
production of phosphate species by cells to induce mineralisation. This study shows 
that a faster mineralisation is induced (at day 3) when the cell medium is supplemented 
in Pi rather than G (day 11). This also shows the ability of this technique to follow the 
mineralisation process as suggested by several studies [69], [70], [74]. In fact, PCA 
allows a discrimination of two pathways of mineralisation with two different clusters at 
day 3 and 7 between control group and cells treated with G vs. cells treated with Pi. 
This model highlights a shift of the phosphate peak position at 956 cm-1 from cells 
treated with G suggesting the presence of intermediate phosphate species such as 
-TCP or OCP [116]. Moreover, spectra of cells treated with Pi exhibit a stable Hap 
crystal compared to those from cells supplemented in G. In fact, Gosling et al. using 
crystallographic analysis have observed changes in crystal formation in 
microcalcifications from breast cancer tissues due to variations in cell 
microenvironment [128]. For instance, in benign lesions with a neutral pH, ACP is a 
precursor and a high carbonate level is found in mature Hap crystal, whilst the pH is 
more acidic for invasive lesions, OCP precursor is involved and a lower carbonate 
content is observed in Hap lattice [128]. However, our findings suggest that -TCP 
may play a role as precursor of Hap formation, suggesting that the process may be 
more complex than previously thought. 
In parallel, the proof-of-concept studies using macro-ATR [123] or O-PTIR [125] which 
have enhanced spatial resolution (0.5 m) show promising results for locating crystal 
deposits in breast cancer cells and need to be investigated. 
Zoladek et al. have demonstrated the potential of Raman micro-spectroscopy for a 
real-time study of apoptosis process in MDA-MB-231 cells. A chamber was 
incorporated into the microscope to reproduce physiological conditions of culture 
(37°C and 5% CO2) to keep cells alive [129]. A similar setup could be used to follow 
in real-time the mineralisation process. 
The FTIR analysis of the in vitro mineralisation was challenging due to a strong 
scattering background in the spectra. A Mie scattering correction was applied using 
the Kohler’s method [75] to correct the baseline in the spectra. Unfortunately, the 
results were not as expected. In fact, it was difficult to obtain a coherent discrimination 




between groups of cells treated with different osteogenic agents from the control 
group. The difficulty in the discrimination could be due to a strong contribution of 
nucleic acids, which could also be associated to the phosphate band between 1200-
900 cm-1. They can interfere in the calculation of C:P ratios. 
Even if our findings show similar spectral characteristics of mineralisation between 
breast cancer cells and breast tissue sections, our mineralisation model is based on a 
2D cell culture, but to recreate the occurrence of microcalcifications in mammary 
glands two main points need to be discussed. Firstly, the use of osteogenic agents to 
induce mineralisation is directed by an upregulation of ALP activity but there is no 
evidence of mineralisation for in vivo breast cells in contact with osteogenic agents. 
The second point is that cells are grown on plastic plate in 2D, which does not directly 
replicate in vivo conditions. In this context, Vidavsky et al. have developed a 3D model 
by creating breast cell spheroids containing microcalcifications (see Chapter 1, section 
1.4.4) by adding calcium and magnesium at similar concentration as blood levels [43]. 
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Vibrational spectroscopy associated with bright light sources, e.g. synchrotron 
radiation, supercontinuum (SC) light or quantum cascade laser (QCL) sources, have 
emerged over the past decades. Their purpose is to provide a rapid and highly 
sensitive approach to gain chemical information in biomedical studies. 
A synchrotron is a source of electromagnetic radiation. This radiation is produced 
when electrons moving around a large ring are accelerated at close to the speed of 
light. This source is characterised by high brightness and covers a broad range of 
wavelengths from IR to the X-ray regime. Its brightness is due to the high concentration 
of the light over a small area, which is reflected in an improvement of the signal-to-
noise ratio (SNR) when deployed in chemical imaging studies [130]. Synchrotron IR 
micro-spectroscopy has been validated and used in various biomedical studies 
including tissue sections [131], fixed or living cells [132], [133], but dedicated large-
scale facilities are needed for these applications. 
Another type of high brightness light source is the supercontinuum (SC) laser, which 
converts laser light into a broad light spectrum [134]. This phenomenon is apparent 
when the laser light is pulsed through a nonlinear optical fibre [134]. SC light can cover 
from ultraviolet to IR range [134]. Borondics et al. have performed a comparison 
between SC and synchrotron radiations and demonstrated the superior SNR achieved 
by the SC source in the measurement of liver tissue section [135]. The first application 
using SC source on biological tissues was made by Petersen et al. showing the 
feasibility of imaging colon tissue sections in the fingerprint region at selected 
wavelengths between 5.7 and 7.3 m (1754 and 1370 cm-1). More investigations are 
necessary but the advantage is that the technology could be easily used in the lab and 
combined with a micro-FTIR system with a better potential than Globar thermal or 
synchrotron sources [136]. 
In parallel, the past few years have seen several demonstrations of mid-IR imaging 
using QCL sources and applied in several studies, especially in bowel diseases [137], 
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[138] but also breast cancer [139], [140]. These applications have been made on 
tissue microarrays (TMA) of breast tissue sections [139], [140]. For instance, Mittal et 
al. have combined four tuneable QCL sources in their setup in order to cover the 
fingerprint region from 1940 to 770 cm-1 (5.2 to 13 m) [140]. TMA have also been 
analysed using commercial micro-FTIR systems with a thermal source and the images 
have been compared to those recorded with the QCL sources. Full spectral range 
(1940-770 cm-1) (Figure 6.1a) and a selection of twelve wavelengths (Figure 6.1b) 
have been recorded in the fingerprint region. Their home-built setup allowed the 
analysis of 101 TMA cores of 1 mm diameter in only 8 h, while 50 days are necessary 
for the commercial micro-FTIR system and for obtaining data with an adequate SNR 
(average of 32 scans). 
 
Figure 6.1 Spectra of five tissue types recorded from a TMA of breast tissue. (a) Point spectra at 
1 cm-1 resolution. (b) Normalised and baseline corrected spectra of twelve selected wavelengths of 
interest. Figure from [140]. 
 
S. Mittal et al. have demonstrated a good potential for breast cancer analysis by 
differentiating tissue subtypes (malignant, benign …). However, the QCL source 
coupled to a micro-FTIR system in the long wavelength region has not been applied 
for the study of breast microcalcifications. In this context, Tseng et al. have developed 
a QCL source coupled to an upconversion microscopy system using raster scanning 
for analysing breast tissue sections. The QCL source covers long wavelengths from 
9.4 to 12 m (1060 to 830 cm-1) in order to get spectral information on the 3 PO43-, 1 
PO43- and 2 CO32- bands at 1030, 960 and 875 cm-1, respectively [98]. This source 
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was coupled to an upconversion system using a silicon detector for improving the 
sensitivity [73]. In this setup, a long wavenumber infrared (LWIR) QCL is shone onto 
a sample, then combined with a near infrared (NIR) beam and finally focused onto a 
silver gallium sulphide (AgGaS2) nonlinear crystal. The mixed signal is upconverted 
into a NIR signal (e.g. 1020 cm-1 to 958.8 nm) and detected via a silicon detector (more 
details about the instrumentation are reported in Chapter 2, section 2.2.3). 
A collaboration was conducted during this PhD as part of the Mid-TECH project with 
Prof. Pederson and Prof. Tidemand-Lichtenberg at the Technical University of 
Denmark. The aim of our study was to test the LWIR QCL source and upconversion 
imaging technology to enable a rapid and precise identification of microcalcifications’ 
composition in breast tissue, with the potential for a cost-effective instrument as a 
clinical tool. 
 
6.2. Analysis of Hap pellets 
 
In order to assess the spectral quality and peak shapes and positions for phosphate 
and carbonate bands in upconverted spectra, an analysis was performed with KBr 
pellets of Hap with different amounts of carbonate substitution. An example is 
illustrated in Figure 6.2 showing spectra from pellets with Hap containing 2.92 and 
7.52 wt.% carbonate substitution measured at a single point with both IR systems. The 
FTIR spectra (Figure 6.2a) show a good agreement with the upconverted spectra 
(Figure 6.2b) in terms of peak positions for phosphate and carbonate ions. 
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Figure 6.2 Spectra recorded from Hap pellets with 2.92 wt.% (red) and 7.52 wt.% (green) 
carbonate substitution using (a) a micro-FTIR Agilent system in the spectral range from 1300 to 830 
cm-1 and (d) an upconversion system from 1060 to 830 cm-1 with 4 cm-1 step. 
 
In the FTIR spectra, the 3 PO43- band is a broad peak between 1200 and 1000 cm-1, 
whilst the 1 PO43- band is a small peak at 962-958 cm-1 and the 2 CO32- band is also 
a small signal at 875 cm-1 [98], [100]. Similar peaks are also found in the upconverted 
spectra with a maximum at 1044, 964 and 875 cm-1. Unfortunately, the 3 PO43- band, 
which is a broad peak, is not entirely covered by the QCL laser. 
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6.3. Analysis of breast tissue sections 
 
After validating the agreement between phosphate and carbonate peak positions in 
Hap pellets, the upconversion system was used to analyse breast tissue sections. A 




Figure 6.3 Comparison between the micro-FTIR imaging system and upconversion system. (a) 
Histological section of breast tissue section (DCIS stage) and H&E stained. (b) FTIR absorption image 
referring to the phosphate peak intensity at 1020 cm-1 recorded with the Agilent imaging system with an 
15x objective and 5.5 m x 5.5 m pixel size. (c) Upconversion absorption image of the phosphate peak 
intensity 1020 cm-1 corresponding to the upconverted signal at 958.8 nm and 1.8 m x 1.8 m pixel 
size, [141]. 
 
Figure 6.3a shows a histological section of breast tissue biopsy stained with H&E, 
whereby the black box denotes a microcalcification area analysed using the FTIR 
imaging system (Figure 6.3b) and upconversion system (Figure 6.3c). In this figure, 
the FTIR image was measured at the phosphate peak intensity corresponding to 1020 
cm-1 while the upconversion system converted the LWIR signal at 1020 cm-1 to NIR at 
958.8 nm. All these micrographs exhibit the same morphological features and the 
microcalcification is represented by the red-to-green regions in the false colour image. 
The absorbance in the microcalcification area (black box) measured with the 
upconversion system is higher than in the FTIR image, owing to the more intense laser 
source having less likelihood of saturation of peaks (as seen in FTIR) used in the 
former system resulting in a higher SNR [142]. Moreover, this microcalcification area 
is approximately 0.5 mm2 in size. The acquisition time for this area is around 5 min for 
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the full spectral range 3900-800 cm-1, a single image with 64 scans and a spectral 
resolution of 4 cm-1 using the FTIR system, whilst this area was measured at 1020 cm-
1 in 30 s using the upconversion system. Nevertheless, the acquisition time for the 
upconversion system depends on the number of wavelengths selected and the speed 
of the xy translation stage (scanning speed of 5 mm/s in x-direction and 10 m in y-
direction) [141], [143]. 
In our study, only few wavelengths are required to discriminate microcalcifications from 
tissue, based on the phosphate and carbonate peaks. The second derivative was 
calculated for the spectral range 1200-830 cm-1 to gain relevant information in this 
region and allow selecting wavelengths of interest for QCL analysis. A series of 
upconverted images taken from breast tissue sections are illustrated in Figure 6.4. In 
this figure, the second derivative spectrum evidences several peaks at 1032, 1020 
and 985 cm-1 for 3 PO43- band [98], 959 and 930 for 1 PO43- band [91], and 875 cm-
1 for 2 CO32- band [98], [100] (Figure 6.4a). These peak positions were used to obtain 
the multispectral upconversion images shown in Figure 6.4b, and random peaks were 
added to cover a maximum of the phosphate region (1040-930 cm-1). There is a good 
discrimination between the microcalcification (red box) and the surrounding tissue. A 
decrease in phosphate signal between 1040 and 930 cm-1 can also be seen. The 
carbonate peak is detected with a low signal at 875 cm-1 in the microcalcification (red 
arrows) which correlates with the second derivative spectrum illustrated above and the 
mean spectrum in single point measured in the same microcalcification (see Appendix, 
supplementary data 5, Figure E.1). 
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Figure 6.4 (a) Second derivative spectrum of a microcalcification extracted from a breast tissue 
section (DCIS stage). (b) Series of upconversion images obtained at 1040, 1038, 1032, 1020, 985, 958, 
950, 930, 875 and 850 cm-1 with 1.8 m x 1.8 m pixel size. Red arrows show carbonate signals in 
microcalcification area. 
 
To demonstrate the potential of the upconversion system, a comparison was made 
between five spectra extracted from the FTIR image and from the upconverted images 
at twelve different wavelengths (Figure 6.5). 
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In both cases, spectra were extracted from microcalcification and surrounding tissue 
(dashed black box, Figure 6.5a). A comparison between the full FTIR spectrum (in 
blue) and the upconverted absorbance for each wavelength (red circles) is plotted in 
a graph for the microcalcification area (Figure 6.5b) and the surrounding tissue (Figure 
6.5c). In the area of microcalcification, 3 and 1 PO43- bands are both present, 
whereas the surrounding tissue does not exhibit specific features for Hap. Due to the 
limit of the FPA detector in the micro-FTIR imaging system, spectra become noisy 
below 900 cm-1 (LWIR region) and the spectral signatures are not considered reliable 
for the 2 CO32- band, however in the upconverted absorption spectrum there seems 
to be present a small signal at 875 cm-1. Overall, there is a good match between the 
two techniques for the microcalcification area. 
 
 
Figure 6.5 Illustration of an (a) upconverted image of microcalcification from breast tissue section 
obtained at 1020 cm-1 (958.8 nm). Spectra extracted from (b) microcalcification area (dashed black box) 
and (c) surrounding tissue (dashed black box) in the spectral range between 1200-800 cm-1 for the FTIR 
image (blue spectrum) and at 1040,1032,1020, 1005, 970, 962, 950, 910, 881, 875, 860 and 850 cm-1 
for the upconverted images (red circles), [141]. 
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Another example of comparison between H&E staining, FTIR and upconverted images 
of breast sections is illustrated in Appendix, supplementary data 5, Figure E.2. It shows 
a good agreement in terms of spatial distribution of microcalcifications in the breast 
tissue. In the same manner as above, several wavelengths were selected from the 
second derivative spectrum and recorded using the upconversion system (see 
Appendix, supplementary data 5, Figure E.3). As previously, a decrease in phosphate 
signal is observed in the range between 1040 and 930 cm-1 and a very low signal at 
875 cm-1 is detected for carbonate band, which is in line with the FTIR spectrum (not 
shown). In parallel, a comparison between FTIR spectra extracted from three different 
areas in microcalcifications (Appendix, supplementary data 5, Figure E.4) shows a 
good match between phosphate and carbonate peaks. Nevertheless, the upconverted 
spectra evidence a higher absorbance than FTIR spectra (as expected and already 





These results demonstrate the potential of upconversion imaging to detect 
microcalcifications in breast tissue sections. The limit at 900 cm-1 in the FTIR imaging 
system due to the MCT-FPA detector means that we were unable to record the 
carbonate peak at 875 cm-1. The use of an LWIR tuneable laser source (9.4 to 12 m) 
enabled us to explore the carbonate peak distribution in the upconverted images. The 
results show a good agreement in terms of spectral features of microcalcifications 
between the commercial FTIR imaging system and the upconversion system. The 
latter setup allows fast acquisition (30 s/upconverted image) for recording of one 
specific wavelength but the inconvenience of this technique is the scanning speed 
[141]. In fact, the acquisition time depends on the speed of scanning, which is 5 mm/s 
in x-direction and 10 m/s in y-direction, but also on the number of wavelengths 
selected [141]. However, the QCL source coupled to an upconversion detection offers 
several advantages. In fact, silicon detectors do not require liquid nitrogen cooling 
compared to MCT detectors, and the QCL is more intense than Globar thermal source. 
Moreover, silicon detectors are cheaper, have a higher sensitivity and a lower noise 
than MCT-FPA detectors. 
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The main inconvenience from QCLs is the need for a series of QCL sources to cover 
a suitable range of wavelengths of interest, which is very expensive [64], [142]. In 
2014, one system (Spero® QCL system) was commercialised (Daylight solution®), 
limited to a spectral range of 1800-900 cm-1 but customisable to 2300-830 cm-1, and 
with a pixel size varying from 1.4 x 1.4 m to 4.3 x 4.3 m (see Figure 6.6) [144]. Since 
then, several studies have emerged using this device on colon tissue sections [138], 
[145] and renal fibrosis [146]. 
 
 
Figure 6.6 Illustration of (a) a micro-FTIR imaging system with a liquid nitrogen-cooled MCT-FPA 
detector and (b) Spero system using four QCL sources coupled to a microscope unit and uncooled FPA 
detector (Daylight solutions®), [144]. 
 
For the next experiments, an improvement is necessary regarding the microscope 
stage in term of scanning speed. Based on the Spero® system (Figure 6.6), additional 
QCL sources could be added to cover the LWIR regime for the entire 3 PO43- band 
(1200-900 cm-1 or 8.3 to 11.1 m) or to cover the 3 CO32- band in the short wavelength 
region (1500-1400 cm-1 or 6.7 to 7.1 m). In fact, this region could bring 
complementary information in the case of frozen sections, where there is no 
interference from paraffin on the carbonate peaks. 
The advantage of silicon detectors is that they are cheaper and more compact than 
MCT detectors in a microscope system. All these new IR sources added in a compact 
system offer a large range of possibilities such as improvement of data quality and 





Chapter 7 : General discussion 
 
The main purpose of this work was to understand the composition of 
microcalcifications expressed in breast cancer using vibrational spectroscopy using 
different approaches, e.g. mineral standards, microcalcifications in breast tissue 
sections, and in vitro mineralisation. For the first time, this study demonstrated the 
potential of the vibrational spectroscopy to follow the mineralisation over time via a 
unique 2D model of breast cancer cell mineralisation. In parallel, the use of an 
innovative setup, mixing a bright source in the long wave regime and a simple 
detection based on silicon detectors, gives new perspectives for analysing breast 
microcalcifications. All these techniques allowed to understand the maturation process 
for microcalcifications and evidenced for the first time that different phosphate species 
were involved during the Hap crystal formation in breast cancer. 
 
7.1. Potential understanding of mineralisation process 
 
The analysis of breast tissue sections and the mineralisation of the breast cancer cells 
evidence the same spectral features in terms of phosphate and carbonate bands 
compared to the mineral standards. Even though the frozen and de-paraffinised 
sections were not the same sample or same section, the de-paraffinisation process 
did not seem to affect the spectral signatures of the microcalcifications. The study 
reveals specific peaks of phosphate and carbonate bands at 960 and 1070 cm-1, 
respectively found in Raman spectra. For FTIR spectra, specific peaks are observed 
at 1030 cm-1 for phosphate and 875, 1408, 1423, 1456 cm-1 for type B carbonate ion 
substitution. Our study does not show the presence of type A carbonate substitution 
in Raman and FTIR spectra (1106 and 881 cm-1, respectively) of the calcium deposits.  
 
Previously, it has been demonstrated that the carbonate content is higher in benign 
lesions [59], which was also expected in our study. However, considering the 
difficulties of evaluating the carbonate content e.g. by curve fitting analysis, integration 
method or PLS model, and also the small number of samples, it is not possible to 
make definitive conclusions. In fact, the evaluation of carbonate content in these 
microcalcifications suggests a high range of carbonate ion substitutions. However, 
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different artefacts could interfere in the calculation. Not only that, with advances in 
spatial resolutions and analysis methods it is now clear that microcalcifications are 
incredibly heterogeneous in nature, potentially including various mineral phases.   
 
The analysis of other mineral standards than cHap (e.g. OCP, ACP, and -TCP) has 
shown similar spectral features to those found in breast microcalcifications. For 
instance, ACP presents the same phosphate peak at 959 cm-1 in Raman spectra as 
cHap with a more significant broadening. Moreover, even if the literature suggests that 
type B carbonate ion substitution is mainly found in biological samples, this does not 
rule out the presence of type A carbonate substitutions in breast microcalcifications; 
as it was suggested by Gosling et al. [128]. All these elements could interfere in the 
calculation of different C:P ratios and the calibration curve. 
 
Using all the literature available, Gosling et al. have proposed a hypothetic model of 
microcalcification formation in mammary gland, which occurs in benign, DCIS, and 
invasive stage of breast cancer (Figure 7.1) [128], which tends to support our 
hypothesis for the presence of different precursors in breast microcalcifications.  
 
 
Figure 7.1 Schematic representation of the hypothetic microcalcification formation in the breast 
from benign to DCIS and invasive cancer stages. From S. Gosling, 2019. 
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Baker et al. have demonstrated that a higher carbonate concentration is observed in 
benign lesions compared to malignant lesions [59]. The incorporation of carbonate 
ions in the lattice induces changes in the crystal shape and size [147]. In fact, the Hap 
crystal size is smaller in case of benign lesions when compared to the crystallites found 
in malignant lesions [128]. Moreover, Gosling et al. have suggested that the ratio of 
type A to type B carbonate substitutions is likely to relate to the stage of pathology. 
Both types A and B are in the lattice of Hap crystal in benign lesions, whereas the level 
of type B substitution increases and the level of type A substitution decreases in case 
of malignant lesions [128]. However, in this work as outlined above, no type A Hap 
was seen in the 18 benign calcifications measured here.  
 
The pH changes in the cell microenvironment have already been demonstrated during 
breast cancer progression [85], and an acidic pH is found for a late stage of breast 
cancer. One of the consequences of these biological changes is that they can affect 
the Hap crystal structure and crystallinity but also its formation and the recruitment of 
different cHap mineral precursors. 
 
The analysis of the in vitro mineralisation of breast cancer cells by Raman micro-
spectroscopy tends also to validate this hypothesis. This study has shown the ability 
of this technique to follow the mineralisation process as suggested by several studies 
[129], [148], [149]. A faster mineralisation is induced (at day 3) when the cell medium 
is supplemented in Pi rather than G (day 11), providing free phosphate ions to the 
cells rather than needing to synthesise it from a precursor. By utilising PCA it was 
possible to clearly determine two pathways of mineralisation with two different clusters 
at day 3 and 7 between control group and cells treated with G vs. cells treated with 
Pi. This model highlights a shift of the phosphate peak position at 956 cm-1 and a width 
slightly higher from cells treated with G suggesting the presence of intermediate 
phosphate species such as OCP [116]. Moreover, information extracted from spectra 
of cells treated with Pi exhibit a stable Hap crystal compared to those from cells 
supplemented in G. However, according to Gosling et al., the crystallographic 
analysis highlights changes in crystal formation in microcalcifications from breast 
cancer tissues due to variations in cell microenvironment [128]. For instance, in benign 
lesions with a neutral pH, ACP is a precursor and a high carbonate level is found in 
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mature Hap crystal, whilst the pH is more acidic for invasive lesions, OCP precursor 
is involved and a lower carbonate content is observed in Hap lattice [128]. In this 
cellular model, the culture medium has a pH of 7.4 maintained by bicarbonate ions 
buffer. However, during the cell growth, cells release metabolites which can change 
the pH and become more acidic, until the medium was replaced after three days. This 
could play a role in the specific mineralisation process modelled here. 
 
In parallel, our curve fit analysis in the phosphate regions suggests also the presence 
of -TCP, which may play a role as precursor of Hap formation and suggesting that 
the process may be more complex than previously thought. In fact, calcium phosphate 
species are important elements in the body in normal physiological conditions e.g. 
bone formation, mineral balance etc. [150]. Among these species, cHap is the result 
of a final solid mineral phase of mineralisation [81]. The application of new techniques 
such as vibrational spectroscopy or X-ray diffraction (XRD) evidences that the 
mineralisation process involves several mineral precursors including OCP, ACP and 
DCPD for the formation of a mature Hap crystal [151]. 
 
Pathological calcifications are more complex, still misunderstood, and the involvement 
of precursor phases is different according to their location in the body. For instance, 
the XRD analysis has revealed cHap, OCP, DCPD and -TCMP in dental calculus, 
whereas cHap, OCP, ACP and -TCMP are found in calcified soft tissues (lung, heart 
…) [80]. Recently, the presence of -TCMP has also been demonstrated in breast 
microcalcifications [42], [114]. 
 
In order to understand the mineralisation process, synthetic systems have been 
investigated using mineral standards. Their synthesis is made in a supervised 
environment, by controlling the concentration of each element (ratios of phosphate, 
calcium, magnesium, carbonate …) but also the temperature and the medium’s pH for 
each reaction [80], [148]. In this context, it was possible to get a schematic 
representation of the transformation of different calcium phosphate species into 
another (Figure 7.2). 
 




Figure 7.2 Schematic diagram of calcium phosphate species transformation in synthetic system. 
The pH, Mg2+ and P2O74- concentrations, phosphate and carbonate amounts were precisely calculated 
and controlled. Each red cross denotes that a reaction is enhanced by a specific factor (e.g. ions, pH 
…). -TCMP: Magnesium-substituted tricalcium phopshate Mg2+: Magnesium ion, P2O74-: 
Pyrophosphate ion. Adapted from [80]. 
 
Legeros et al. have summarised different pathways for the transformation of cHap, 
ACP, OCP and -TCMP (Mg-substituted tricalcium phosphate) [80]. Hap is the most 
stable form of phosphate species in neutral or basic conditions [81] and is formed from 
different precursors and by different reactions of hydrolysis or precipitation [80]. Lotsari 
et al. have suggested that ACP has a contribution in the cHap formation during bone 
formation [152]. In fact, ACP could spontaneously be transformed into Hap in 
physiological conditions [81]. In parallel, a medium rich in CO32- induces the hydrolysis 
of ACP into cHap, but this reaction is inhibited in presence of an excess of 
pyrophosphate (P2O74- ions) or Mg2+ ions [80]. Suzuki et al. have also suggested the 
importance of OCP during bone formation [151]. At neutral pH, OCP can transform 
into cHap by hydrolysis with a high concentration of carbonate and this reaction is 
irreversible [80], [151]. On the other hand, an acidic environment and a very low 
concentration of carbonate induce the OCP [80]. 
 
In a synthetic environment, the formation of Hap crystal from -TCP depends on the 
pH of the medium, but this reaction is inhibited in presence of a high concentration of 
Mg2+ at room temperature [81]. The presence of -TCP is more controversial due to 
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the fact that this pure form is not found in physiological conditions, although only Mg2+ 
substituted -TCP (-TCMP) is found [153]. The potential presence of -TCP based 
on our curve fit model is in line with the study led by Scimeca et al. [42]. It is possible 
to distinguish by X-ray diffraction (XRD) -TCP from -TCMP by a shift in the XRD 
peaks because Mg2+ replaces Ca2+. For the FTIR spectroscopy, in both cases, spectra 
exhibit spectral features of -TCP [154]. Until now, there is no data available based on 
the discrimination between both standards using Raman micro-spectroscopy. 
 
The type of phosphate precursors at different stages of breast cancer depends on its 
microenvironment. For instance, neutral pH and high carbonate level are found in 
benign lesions, which combine all factors to convert ACP to cHap (as described above 
in synthetic environment) [80], [81]. According to Gosling et al., the hydrolysis of ACP, 
rich in carbonate, is a good candidate to facilitate the incorporation of carbonate ion 
substitutions in Hap lattice. On the contrary, OCP is favoured in acidic environment to 
facilitate the cHap formation [80], which is the case in malignant lesions.  
 
However, at the end of this thesis, it is impossible to determine if all these reactions 
from a mineral to another happen in biological tissues but a majority of them are 
certainly present in pathological mineralisation [40], [80]–[82]. 
 
7.2. New spectroscopic tools for the breast microcalcification 
analysis 
 
Over the past decades IR spectroscopy associated with bright light sources, e.g. 
synchrotron radiation, supercontinuum (SC) light or quantum cascade laser (QCL), 
sources have emerged and their purpose is to provide a rapid and highly sensitive 
approach to gain chemical information in biomedical studies. A collaboration with Prof. 
Petersen and Prof. Tidemand-Lichtenberg from DTU gave us the opportunity to have 
access to their unique upconversion technologies coupling a commercially available 
LWIR QCL source with a upconversion system. The use of novel IR spectroscopic 
technologies based on QCL sources and upconversion detectors can be an important 
approach to gain enhanced spectral information from selecting a specific wavelength, 
for instance around 875 cm-1 (11.4 µm) corresponding to the carbonate peak, which 
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is difficult to achieve with our MCT-FPA FTIR system. These results demonstrate the 
potential of upconversion imaging to detect microcalcifications in breast tissue 
sections. Moreover, it is particularly effective for performing rapid spectral imaging at 
discrete wavelengths. This technology can potentially be translated into rapid biopsy 
screening for breast cancer in a clinical setting as a complement to other procedures. 
Vibrational spectroscopy could be used in the breast screening routine recommended 
by the NHS. The mammographic images would give information about the spatial 
distribution and the size of the microcalcifications. In complement, the vibrational 
spectroscopic analysis would bring all the chemical information. Ideally, by combining 
these techniques, a system of bare code could be design where a chemical property 
is related to a shape and size of microcalcification or a stage of breast cancer. All 
these new technologies (IR sources and detectors) can be combined in a compact 
and relatively cheap system (£30k-50k), which offers a large range of possibilities such 
as improvement of data quality and faster acquisition time.  
 
7.3. Future work 
 
This work can be extended in terms of biological samples but also the mineral 
standards for the analysis of breast microcalcifications: 
• The size of cohort samples. 
By increasing the number of samples, it opens possibilities to find other 
minerals than cHap but also increases the reproducibility of the findings in such 
a heterogeneous population of samples. 
• Refine the calibration curve. 
An increase of samples with different amount of carbonate ion substituted in 
Hap powders, for instance between 0.5 and 6 wt.% of carbonate content usually 
found in biological samples [38], is necessary to be more accurate in the 
estimate of carbonate content in biopsy samples. 
• Different type of cHap standards could be used such as type A or a combination 
of type A and B in Hap lattice [100]. 
Even if the literature suggests that type B carbonate ion substitutions are the 
main type of substitution found in biological samples, exploring type A 
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carbonate ion substitutions gives opportunities to find them in breast 
microcalcifications [128]. 
• Finding a supplier for dicalcium phosphate dihydrate (DCDP) standard, which 
is also considered as a cHap precursor phase [80], [151], could be useful for 
comparison with biological microcalcifications. 
In fact, at low pH and high concentration of CO32-, DCPD could also be 
transformed into cHap [80]. 
 
The mineralisation in different contexts has been analysed by several approaches 
(listed below), which can lead us to apply them in the microcalcification study: 
• Techniques based on X-ray (XRD, X-ray fluorescence (XRF)…) could give the 
elemental composition of microcalcifications [114], [115].  
For instance, the analysis by XRD of a small number of microcalcifications has 
shown the presence of -TCMP in small concentrations, which provides 
promising results [42], [114] and could be useful to identify other mineral phases 
in breast microcalcifications. 
• Stimulated Raman Scattering (SRS) to image, with high resolution and speed, 
the spatial distribution of carbonate and phosphate in microcalcifications [155]. 
• Raman micro-spectroscopy of live cells, in real-time, to assess cell 
mineralisation day by day [129]. 
• As discussed in Chapter 5, a 3D model based on breast cell spheroids 
containing microcalcifications as a new in vitro model [43]. 
 
The relationship between the microcalcification and its microenvironment is still not 
fully understood. Nevertheless, Morgan et al. have shown that the Hap crystal 
enhances the mitogenesis and, as a consequence, the cell proliferation and the 
production of matrix metalloproteinases (MMPs) [44]. Their upregulation can lead to a 
collagen degradation, which induces ECM remodelling and migration of epithelial cells, 
and an epithelial organisation in breast tissue [149], [156]. In this context, an 
exploration of the architecture of collagen fibres by multiphoton microscopy such as 
SHG could be helpful for locating collagen networks surrounding the 
microcalcifications [113]. 
  





This work aimed to untangle the different mineral phases found in breast 
microcalcifications. Vibrational spectroscopy has shown its potential for the 
investigation of microcalcifications by giving information about their chemical 
composition and their spatial distribution in breast tissues. This work also contributes 
to understanding the mineralisation process in pathological conditions. 
 
Therefore, further detailed study of microcalcifications associated with breast cancers 
is important both for an understanding of the disease progression from a diagnostic 
and prognostic perspective but also for the development of a potential therapeutic 








A. Appendix - Supplementary Data 1 
Figure A.1 Patient consent form given by the RD&E Tissue Bank to patients prior to collect 
samples for the study. 
 
CONSENT STATEMENTS  Please 
Circle 
I confirm that I have had opportunity to consider the information, ask 
questions and have had these questions answered satisfactorily.   
YES / NO 
I agree to donate samples and data available during my routine clinical 
care to the RD&E Tissue Bank and I give permission for NHS staff to 
obtain information from my medical record for the purposes of research. 
YES / NO 
I understand that my samples and hospital data will be stored securely at 
the Royal Devon & Exeter NHS Foundation Trust Tissue Bank in Exeter. 
YES / NO 
I understand that genetic material may be extracted from my samples and 
used for future research into the causes of disease.   
YES / NO 
I understand that my agreement is voluntary and that I am free to 
withdraw my samples and associated data any time without giving any 
reason and without my medical care or legal rights being affected. 
YES / NO 
I understand that with the agreement of a steering committee the tissue 
bank will provide my anonymised data and samples to researchers for 
the purpose of understanding disease and improving healthcare. 
YES / NO 
OPTIONAL STATEMENTS 
I give permission for researchers to feedback information to my referring 
hospital doctor that might be relevant to:  
a) my current condition   
b) other conditions that might affect me but have not yet been identified 
c) conditions that might affect my family in the future 
 
 
YES / NO 
YES / NO 
YES / NO 
 
Donor Name: ………………………………………………..  
Date …...................................    Signature ……………………………… 
Consented by ……………………… Date …………… Signature …………………… 




This is a copy of the consent form that you signed when you agreed to join the RD&E Tissue 
Bank.  The Donor Code on the top right hand side of the consent form is the anonymous code 
that we will use to identify you.  If, in the future you would like to withdraw your samples from 
the RD&E tissue bank and make any other changes to your consent please telephone us at 
RD&E Tissue Bank on 01392 408178 quoting this donor code and your first and last initial. 
 
If you would like to have a say in which studies have access to the RD&E tissue bank you may 







Figure A.2 Breast tissue donation form summarising clinical information about biopsy samples 
completed by RD&E Tissue Bank. WLE: wide local excision 
 






RELEVANT CLINICAL INFORMATION 
 
Date of Surgery Tissue Donation: .…/.…/20…. 
 
Site: Right / Left      BMI: 
 
Breast biopsy sample obtained? Yes / No 
 
Surgical procedure Undertaken: WLE / Mastectomy 
 
Additional Procedures: SNB / Axillary Clearance / None / Other 
 
Diagnosis type: Screening / symptomatic 
 
ER Status: Positive / Negative Intensity: Weak / Mod / Strong Percentage: 
 
Her2 Status: Positive / Negative   
 
Family History: Yes / No Relationship:   Age at diagnosis: 
 
Menopausal status: Pre / Peri / Post 
 
HRT use: Yes / No Age commenced:  How many years: 
 
Current/Previous Breast Ca treatment: Yes / No Type: 
 










Figure B.1 Average of 5 Raman spectra from pure Hap powder from Sigma Aldrich. Spectrum was 











Figure B.3 Results of Gaussian and Lorentzian peak decomposition applied to the FTIR spectra of carbonated Hap compounds in the spectral range 1200-







Figure B.4 Results of Gaussian and Lorentzian peak decomposition applied to the FTIR spectra of carbonated Hap compounds in the spectral range 890-






Figure B.5 Results of Gaussian and Lorentzian peak decomposition applied to the FTIR spectra of ACP, β-TCP and OCP compounds in the spectral range 








Figure B.6 Results of Gaussian and Lorentzian peak decomposition applied to the Raman spectra of carbonated Hap compounds in the spectral range 






Figure B.7 Results of Gaussian and Lorentzian peak decomposition applied to the FTIR spectra of carbonated Hap compounds in the spectral range 1100-






Figure B.8 Results of Gaussian and Lorentzian peak decomposition applied to the Raman spectra of ACP, β-TCP and OCP compounds in the spectral 




Table B.1 Wavenumbers of FTIR peaks of ACP, β-TCP and OCP and their assignment based on 
the peak decomposition and the literature, [86], [88], [89], [91], [94], [98], [99], [101]. 
 
 
Table B.2 Raman shifts of ACP, β-TCP and OCP peaks and their assignments based on the peak 






Figure B.9 Linear regression of the plot of C:P ratio vs. % CO32- substitution in cHap pellet samples. 
Data were obtained from FTIR spectra as the ratio of the total carbonate to phosphate peak areas. Two 
replicates were performed in those experiments. Values are mean ± SD. Regression equation: y= 
1.82·10-3 x; R2 = 0.96. 
 
 
Figure B.10 Linear regression between the ratio C:P vs. % of CO32- substitution in cHap pellet 
samples. Data were obtained from FTIR spectra as the ratio of the total carbonate to phosphate peak 
areas. Two replicates were performed in those experiments. Values are mean ±SD. Regression 







Figure B.11 Linear regression between the ratio C:P vs. % of CO32- substitution in cHap pellet 
samples. Data were obtained from FTIR spectra as the ratio of the total carbonate to phosphate peak 
areas. Two replicates were performed in those experiments. One replicate has been performed. Values 





Table B.3 Peak areas for the subbands of FTIR spectra from cHap pellets based on the peak decomposition analysis. 
 




Table B.5 Peak areas for the subbands of Raman spectra from cHap pellets based on the peak 
decomposition analysis. 
 
Table B.6 FWHMs for the subbands of Raman spectra from ACP, β-TCP and OCP pellets based 
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Figure C.1 Histological sections with H&E staining and corresponding FTIR spectra at three stages 
of breast cancer: (a) Benign, (b) DCIS low grade and (c) IDC grade 2. An average of 10 spectra were 





Figure C.2 Results from curve fit analysis applied to Raman spectra. Histological sections with 
H&E staining and comparison of Raman spectra of de-paraffinised tissues of three breast lesions: (a) 
Benign, (c) DCIS low grade and (e) IDC grade 2. (b,d, and f) Spectra were truncated to the phosphate 
band at 990-930 cm-1 and to the carbonate band at 1100-1020 cm-1 and baseline corrected. For each 






Figure C.3 Results from curve fit analysis applied to the Raman spectra. (a and c) Visible images 
of de-paraffinised breast tissue sections (benign stage). Red boxes denote the regions where Raman 






Figure C.4 Results from curve fit analysis of FTIR spectra from frozen breast tissue (benign lesion). 
(a) Second derivative spectrum between 1200 and 830 cm-1. Curve fit analysis was performed on 
spectra truncated to (b) the phosphate band at 1200-900 cm-1 and (c) the carbonate band at 890-830 




Table C.1 Predicted phosphate species in frozen and paraffinised/de-paraffinised breast tissue microcalcifications using sub-peak positions obtained by 
curve fit analysis performed on Raman and FTIR spectra for three breast lesions: B: Benign, D: DCIS, and I: invasive cancer. Double red arrows are added to 








Figure D.1 Mean Raman spectra collected from breast cancer cells after 7 days (a) and 14 days 
(b) of mineralisation. Pi: inorganic phosphate, OC: osteogenic cocktail, Dex: Dexamethasone, Phe: 
Phenylalanine, Cys: Cysteine, Tyr: Tyrosine. Cells were treated with Pi+Dex and OC+Dex (G). Non-







Figure D.2 ATR-FTIR spectroscopy analysis of breast cancer cells treated with (a) Pi+Dex and (b) OC + Dex. For both conditions, FTIR images are based 
on the Amide I and phosphate peak intensities. Red and white arrows correspond to the location of high phosphate intensity found in calcium deposits. Figure 






Figure D.3 FTIR imaging spectroscopy analysis of breast cancer cells treated with OC + Dex. FTIR 
images are based on the Amide I and phosphate peak intensities. Red and white arrows correspond to 
the location of high phosphate intensity found in calcium deposits. Figure provided by M. Tobin and J. 






Figure D.4 O-PTIR spectroscopy analysis of breast cancer cells treated with OC + Dex after 11 days of mineralisation. Images are based on the Amide I, 
phosphate peak intensities, and the ratio protein-to-phosphate ratio. Red arrows correspond to the location of high phosphate intensity found in calcium deposits. 





Figure D.5 Results from curve fit analysis of Raman spectra for cells treated with Pi + Dex at day 7, 11 and 14 and OC+Dex (βG) at day 11 and 14. Spectra 




Table D.1 Calculation of Carbonate-to-phosphate ratio and carbonate amount in breast cancer 
cells after 3, 7, 11 and 14 days of mineralisation for each replicate after Pi and G treatments. 










Figure E.1 FTIR spectrum in single point measured from a microcalcification in breast tissue 
section (DCIS stage) in the spectral range 1200-830 cm-1 including phosphate and carbonate regions. 





Figure E.2 Comparison between the micro-FTIR imaging system and upconversion system. (a) 
Histological section of breast tissue section (DCIS stage) and H&E stained. (b) White light image of a 
breast tissue section without staining mounted onto BaF2. (c) FTIR absorbance image referring to the 
phosphate peak intensity at 1020 cm-1 recorded on the spectral range 3900-900 cm-1 with the Agilent 
imaging system with an x15 objective and 5.5 m2 pixel size. (c) Upconversion absorbance image at 





Figure E.3 (a) Second derivative spectrum of a microcalcification extracted from breast tissue 
section (DCIS stage). (b) Multispectral upconversion images obtained at 1040, 1038, 1032, 1028, 1020, 







Figure E.4 Upconverted image of a microcalcification from breast tissue section obtained at 1020 
cm-1. Spectra recorded from three microcalcification areas (red squares) in the spectral range between 
1200-900 cm-1 for the FTIR image (blue spectrum) and at 1040, 1038, 1032, 1028, 1020, 1017, 1014, 
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c. Summer schools as part of the Mid-TECH project 
 
• Berlin, Germany, 29 February – 6 March 2016. 
Purpose: Basics of physics of mid-IR light sources and mid-IR detection, Physics of 
key applications, limitations and options in mid-IR instrumentation, work on and solve 
real problems in these areas, both in a group and as individuals. 
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individually prepare a mid-IR case (a 1-page description of a mid-IR invention or 
application). 
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Purpose: Fundamental spectroscopy with cutting edge clinical practice 
Fundamentals of Infrared Spectroscopy, Spontaneous Raman Spectroscopy, Non-
linear Raman Spectroscopy, experimental design, clinical problem solving sessions, 
spectrometer design, clinical perspectives, spectral Interpretation and chemometric 
analysis. 
 
• Lund, Sweden, 18-21 June 2018. 
Purpose: Basics of Molecular spectroscopy. Mini Mid-TECH seminars to provide a 
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